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CHAPTER 1: INTRODUCTION
Prostate Cancer:
	
  

Prostate cancer is one of the most common cancers among American men and

is the second leading cause of death among them in the United States [1]. Prostate
cancer is slow growing and the majority of deaths are from metastatic disease.
Metastatic prostate cancer generally localizes in the bones and lymph nodes [2]. The
causes leading to prostate cancer metastasis and the mechanisms by which cells
escape from the primary site and intravasate into the circulation to spread to distant
organs, e.g. bone, is poorly understood [2].
Diagnosis of Prostate Cancer:
Recent advances in diagnostic methods have enabled detection of prostate
cancer at an early stage thereby reducing the number of deaths from metastasis. These
methods include the PSA test, Digital Rectal Examination (DRE), trans-rectal ultrasound
and trans-rectal biopsy [3]. Two of the most commonly used methods for diagnosis are
the PSA test and DRE [2, 4].
Blood Test for Prostate-Specific Antigen (PSA): PSA, also known, as Kallikrein is a
serine protease enzyme that was discovered by Dr. Richard J. Ablin and has been
approved by FDA for annual screening of prostate cancer in men of age 50 and older.
Serum PSA levels are higher in patients who have prostate cancer compared to men
with healthy prostates. PSA is measured from a blood sample by Enzyme Linked
Immuno-Absorbance Assay (ELISA), where the normal level of PSA in human blood is
4 ng/ml. Free PSA in blood beyond 10 ng/ml indicates additional tests are necessary to
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check for cancer. As there were many false positives in some patients, PSA test is more
of a predictive test that needs to be verified by additional tests. Success of the PSA test
was one factor responsible for the decline in the number of deaths that occurs due to
prostate cancer [5, 6].
Digital Rectal Examination: This is a physical examination of the prostate where the
prostate is directly palpated for irregularities from inside the rectum. However, with this
method only 10% of the gland can be examined. Furthermore performance in detecting
abnormalities varies greatly, and agreement between examiners is low. Therefore
additional markers are necessary to augment existing PCa tests. [2, 3, 7].
Prostate Cancer Pathology and Grading
Once diagnosed, prostate cancer is classified into different grades and stages that
are used to predict responsiveness to a specific cancer therapy, such as radiotherapy or
surgery. The Gleason grading system developed by Dr. Donald F. Gleason is the most
commonly used method to grade prostate cancer tissues based on the histologic
pattern of arrangement of cancer cells in Hematoxylin and Eosin (H&E) stained prostate
tissue sections [8]. Gleason grades include five basic grade patterns (Figure 1.1). To
generate a histologic score, ranging from 2 to 10, the primary and the secondary grade
patterns are added. “Gleason grade has been linked to a number of clinical end points,
including clinical stage, progression to metastatic disease, and survival” [6, 8, 9].
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Figure 1.1: Gleason grading system. This was developed by Dr. Donald F. Gleason and is the
most commonly used method to grade prostate cancer tissues based on the so called
“architecture” of H&E-stained prostatic tissue sections [8].

Treatment Options:
There are several methods available for treating men with prostate cancer.
These include surgery, chemotherapy, cryotherapy, hormonal therapy, radiation, High
Intensity Focused Ultrasound (HIFU), and "watchful waiting” [10][2]. Treatment options
vary between patients depending on the patient’s age, stage and grade of the disease.
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The treatment that is best for one man may not be best for another, and yet another
may have a combination of treatments [2].
Risks Factors for Prostate Cancer:
Common risk factors that are associated with prostate cancer include: age, race and
diet [2, 11].
Age over 65: Age is the main risk factor for prostate cancer. In the United States, most
men with prostate cancer are over 65. This disease is rare in men under 45. There is a
racial component and African-American men should be screened earlier for prostate
cancer at age 40 [2, 11].
Race: Prostate cancer is more common among African-American men than Caucasians
or Hispanic men. It is less common among Asian and Native American men. Also the
rate of men dying from prostate cancer has varied, depending on their race and
ethnicity where recent data shows that, African-American men were more likely to die of
prostate cancer than any other ethnic group. Caucasian men had the second highest
rate of deaths from prostate cancer, followed by Hispanic, Native American, Alaskan
Native, and Asian/Pacific Islander [12, 13].
Diet and Prostate Cancer: Diet is also considered an important risk factor for prostate
cancer. Epidemiologic studies have suggested that high consumption of fat and red
meat, and lower consumption of fruits and vegetables contributes to morbidity [11, 1417]. Animal fat is especially rich in arachidonic acid, whose metabolites have been
shown to affect prostate cancer progression [16, 17].
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Arachidonic Acid Metabolism:
Arachidonic acid (AA) is an essential component of mammalian cell membranes
and plays a critical role in the synthesis of eicosanoids [18]. Arachidonic acid and its
precursor, linoleic acid, are major components in animal fats and many vegetable oils
[17]. Arachidonic acid is mobilized by phospholipase A2 (PLA2) from cellular membrane
glycerolipid pools in response to many stimuli such as cytokines and growth factors
(15). Arachidonic acid is present in membrane phospholipids and is released by
phospholipase A2 and can be oxidized by three distinct enzymes Cyclooxygenase
(COX), Lipoxygenase (LOX), or P450 epoxygenase into three distinct pathways to form
a variety of eicosanoids as shown in Figure 1.2 [18]. “Eicosanoids are 20-carbon lipid
molecules derived from the enzymatic breakdown of membrane lipid precursors, chiefly
arachidonic acid” [18]. These bioactive metabolites of arachidonic acid are potent in
several physiological and pathological processes such as inflammation, asthma, and
cancer [19, 20]. Lipid mediators generated by these enzymes are involved in a wide
variety of cellular and molecular pathways, including but
not limited to apoptosis, cell survival, proliferation, chemotaxis and senescence [19, 20].
Lipoxygenease Pathway:
	
  

In the	
   lipoxygenase pathway, AA is oxidized by several enzymes resulting in the

formation of hydroxyeicosatetraenoic acids (HETEs), leukotrines, lipoxins, and
hepoxilins. “The chief enzymes of the LOX pathway are the 5- LOX, 12-LOX, and 15LOX enzymes whose names are derived from the position in which molecular oxygen is
inserted into the arachidonic acid backbone” [21].
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Figure 1.2: Schematic
overview of major bioactive lipids derived from arachidonic acid
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S

2

NHCO(CH2)2CHCOOH

Cytochrome P450) into three pathways NH[22].

OH

HO

O

2

HO

The predominant bioactive products of the 5-LOX pathway are the leukotrienes
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Fig. 1 a, b Bioactive eicosanoids derived from the arachidonic acid
cascade. Arachidonic acid is metabolized by three pathways—the
cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450
(CYP) pathways. Schematic overview of major mediators and their
metabolites (blue); enzymes (black, boxed) and biological role (green).
Inhibitors (red ovals) and agonists (green ovals). HETEs Hydroxyeicosatetraenoic acids, EETs epoxyeicosatrienoic acids, CYP cytochrome

P450 enzymes. MS-PPOH is a selective inhibitor of a subset of
epoxygenases. HET0016 is a selective inhibitor of the ω-hydroxlase
CYP4A. The sEH inhibitor (soluble epoxide hydrolase inhibitor)
increases EET levels by acting as an agonist of the EET pathway.
14,15-EEZE is a putative EET receptor antagonist. PGE2 prostaglandin
E2, PGI2 prostacyclin, LTA4 leukotriene A4, DHET dihydroxyeicosatrienoic acid, 20-OH PGE2 20-hydroxy-prostaglandin E2

leukotriene formed by action of 5-LOX on AA, which is then hydrolyzed to LTB4 by
LTA4 hydrolase [21]. Action of LTC4 synthase on LTA4 can also give rise to the
membrane
bioactive eicosanoidsnamely
[1]. Eicosanoids
are generated
via the [21,
cysteinyl leukotrienes,
LTC4
and LTD4
23].through
oxidation of the 20-carbon chain present on arachidonic acid or
other related fatty acids [2]. During processes, such as
inflammation, arachidonic acid is released from the cell

the activation of phospholipase A2 [1].
Arachidonic acid is metabolized by the CYP ω-hydroxylases
to 7-, 10-, 12-, 13-, 15-, 16-, 17-, 18-, 19-, and 20-HETEs, the
principal metabolite being the pro-inflammatory 20-HETE [4].

Another key enzyme of the LOX family is 12-LOX. The three important isoforms
are platelet-type, epidermal, and leukocyte-type 12-LOX that act on AA to result in the
synthesis of 12(S)-HETE [21]. It is known that 12-LOX and its product 12(S)-HETE is
involved in the disease process of a variety of cancers including colon carcinoma,
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melanoma, human glioma, prostate and breast cancer [18, 20]. Studies have also
shown that 12(S)-HETE has a wide range of biological functions and has been
implicated in prostate cancer metastasis through its action on endothelial cell retraction
and integrin regulation [18, 24, 25]. Another key member of LOX family is 15-LOX,
which exists as two isoforms; 15-LOX-1 and 15-LOX-2 [18, 20]. Action of 15-LOX on
arachidonic acid gives rise to 15-HETE [21].
P450 Epoxygenase Pathway:
Cytochrome P450-dependent metabolism of AA includes two distinct pathways:
the ω-hydroxylase and epoxygenase pathways [22]. The ω- hydroxylases of the 4A and
4F gene families of cytochrome P450 (CYP4A and CYP4F) convert arachidonic acid to
autacoids

such

as

hydroxyeicosatetraenoic

acids

(HETEs)

[22,

26].

20-HETE is the principal isoform of this pathway and can be vasoconstrictive [27, 28].
The epoxygenase pathway occurs in several tissues including liver, kidney, and the
cardiovascular system [26]. This latter pathway includes two enzymes, CYP2C and
CYP2J, which generate epoxyeicosatrienoic acids (EETs) that are known to have
vasodilatory activity [22, 26]. Guo et al. have shown that 20-HETE can stimulate
endothelial cell proliferation and VEGF expression in vitro suggesting that CYP ωhydroxylase may play an important role in tumor growth and angiogenesis [29, 30]. In
Non Small Cell Lung Cancer (NSCLC) cells, CYP ω-hydroxylase enhanced cellular
invasion in vitro as well as angiogenesis and metastasis in vivo and significantly
increased the expression of VEGF and MMP-9 in vitro and in vivo [29, 30].
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Cyclooxygenase Pathway:
	
  

Most prostate cancer biology has focused on the role of COX and LOX

enzymes [18, 20, 31, 32]. Cyclooxygenase has two isoforms that differ mainly in
regulation of their expression and tissue distribution. COX-1 is widely expressed in most
tissues, whereas COX-2 expression is normally absent, but can be induced by
numerous stimuli such as growth factors, TNFα and inflammation [33, 34]. COX-2 is
over expressed in many human non-endocrine and endocrine tumors including those of
the colon, breast, prostate, brain, thyroid, and pituitary [33, 35]. Cyclooxygenase
catalyzes the conversion of AA into a prostaglandin intermediate, PGH2, which is in turn
oxidized by several other enzymes that can form two classes of eicosanoid products,
namely prostaglandins (PGI2, PGE2, PGD2, PGF2a) or thromboxanes (TXA2) (Figure1.3) [36-38].
Prostaglandin E2 (PGE2) is formed by the action of prostaglandin E synthase
(PGES) on Prostaglandin H2 (PGH2). Among the COX metabolites, PGE2 has been
widely implicated in various steps of cancer development and progression such as
angiogenesis, cell survival, proliferation, and chronic inflammation [21, 31, 35].
PGH2 can also be acted on by thromboxane synthase (TXA2S) that catalyzes its
conversion to thromboxane A2 (TXA2), a potent vasoconstrictor and an inducer of
platelet aggregation [39, 40] [36, 37, 41]. Additionally the enzyme prostacyclin synthase,
antagonizes the effect of TXA2S by catalyzing the conversion of PGH2 to prostacyclin I2
(PGI2) that opposes the action of TXA2, namely causing vasodilation and inhibiting
platelet aggregation [42, 43].
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Figure 1. Production and Actions of Prostaglandins and Thromboxane.
Arachidonic acid, a 20-carbon fatty acid containing four double bonds, is liberated from the sn2 position in membrane phospholipids by phospholipase A2, which is activated by diverse stimuli. Arachidonic acid is converted by cytosolic prostaglandin G/H
synthases, which have both cyclooxygenase (COX) and hydroperoxidase (HOX) activity, to the unstable intermediate prostaglandin
H2. The synthases are colloquially termed cyclooxygenases and exist in two forms, cyclooxygenase-1 and cyclooxygenase-2. Coxibs
selectively inhibit cyclooxygenase-2. Prostaglandin H2 is converted by tissue-specific isomerases to multiple prostanoids. These
2
bioactive lipids activate specific cell-membrane receptors of the superfamily of G-protein–coupled
receptors. Some of the tissues
in which individual prostanoids exert prominent effects are indicated. IP denotes prostacyclin receptor, TP thromboxane receptor,
DP prostaglandin D2 receptor, EP prostaglandin E2 receptor, and FP prostaglandin F2a receptor.
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Figure 1.3: Generation of the prostanoids through metabolism of arachidonic acid by the
COX pathway. In the first step of the generation of TXA , COX-1 and COX-2 isoforms are
responsible for the conversion of AA to PGH2. Thromboxane synthase (TXA S) then catalyzes
the conversion of the COX product, PGH2 to TXA2 [44].
different. The dependence of the lesions on cyclooxThe biochemical selectivity of a particular drug, as
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testinal complications, such as perforation, obstructo inhibit the activity of cyclooxygenase-2 and cyclotion, and bleeding. Indeed, the hemorrhagic nature
oxygenase-1
by 50 percent
(Fig. 2).23-26
However,
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P450 epoxygenase
family
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[45]. The
2 of
2 as
tric mucosa. Finally, the low incidence of these events
biochemical selectivity with the use
such
means that many patients must be studied for pro“preferential cyclooxygenase-2 inhibitor.”
periods of treatment to detect the differences
How well do the results of these in vitro assays
enzyme longed
plays
a
role
in
several
pathophysiological
processes including hemostasis,
21,22
between drugs reliably.
predict selectivity when the measurements are per-
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in lung, platelets, kidney, stomach, duodenum, colon and spleen [46, 48]. Its expression
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is reported to be closely associated with cardiovascular, renal, and inflammatory
diseases [49].
TXA2 is very unstable in aqueous solution, and becomes hydrolyzed within 30s to
the biologically inactive TXB2 [36, 50]. Due to its very short half-life, TXA2 functions as
an autocrine or paracrine mediator in the nearby tissues surrounding its site of
production [48]. TXA2 is responsible for multiple biological processes through the cell
surface TXA2 receptor, or T-Prostanoid, receptor (TP) [46]. TXA2S, and TP are the two
important components necessary for the functioning of this potent bioactive lipid
signaling pathway [46].
Thromboxane A2 Receptor:
Ushikubi et al. first purified TXA2 receptor protein from human blood platelets in
1989 [51]. In 1991, a cDNA for the human TP receptor was originally cloned from
placenta and the platelet-like MEG-01 cell line by Hirata et al. [52, 53]. Raychowdhury et
al. later isolated a cDNA encoding a second isoform of the TP receptor from a human
umbilical vein endothelial cell (HUVEC) cDNA library [53, 54]. Thus, to date there are
two receptors for TXA2 in humans, termed TPα from human placenta and TPβ from
endothelial cells [53, 55, 56]. In humans, these cDNAs represent alternative splice
products of the same TXA2 receptor gene. In all other species, it is only expressed as a
single isoform, TPα [52, 54, 57]. The physiological significance of the existence of two
receptors for TXA2 in humans, but not in other species is still not well understood.
Human TPα and TPβ are typical G-protein coupled receptors (GPCR) that share the
first 328 amino acids but differ in their C-terminal tail, where TPα has a shorter Cterminal cytoplasmic tail than the TPβ isoform (15 versus 79 residues) [52-54] (Figure-
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1.4). Ligand binding sites on the TP receptor are in its extracellular region and are
identical in both splice variants. Therefore, differences in function between TPα and
TPβ likely reside in the complement of G-proteins associated with their C-termini [5759].
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Fig. 2 Structures of TPα and
TPβ receptor proteins. The
TXA2 receptor (TP) is a typical
G-protein-coupled receptor
that is expressed as two different
isoforms in humans—TPα
and TPβ. TP isoforms share the
first 328 amino acids but
differ in the length of the
C-terminal cytoplasmic tail with
TPα shorter than the TPβ
isoform (15 versus 79 residues)
[24, 25]

	
  
multiple cancers indicating the extensive nature of these
TXA2 biosynthesis in PCa cells [45]. Increased TXA2S
effects and the widespread clinical applicability of targeting
and activity in PCa cells augmented cell
Figure. 1.4: Structures of TPα and expression
TPβ Receptor
Proteins. TPα and TPβ are encoded by the
these pathways as adjunct therapy in cancer [30–32, 34].
migration but had minimal effect on cell cycle progression
or
survival
indicating
that
TXAand
might
2S activity
single TP receptor gene, on chromosome 19p13n3 [31],
arise
bycontribute
a novel differential splicing
2.1 Role of thromboxane A2 signaling in prostate cancer
to PCa progression through modulating cell motility [45].
In a study conducted
on tissue samples
patients,
mechanism within exon 3, whereby nucleotides
984–1642
of from
the46TPα
mRNA behave as an
with well-documented histological and molecular data,
Prostate cancer (PCa) is one of the most common cancers
increased
TXA2S and COX-2 expression were observed
amongintron
men in the
USA and
is the
second leading
causemRNA
of
(intron
2b)
within
the TPβ
[52-54].
death in this population [35]. Strong correlations exist
in tumors. In the same study, TP expression was higher in
between diets high in fat (especially from red meat) and
malignant tissues (high-grade prostatic intraepithelial neoPCa [36–38]. As TXA
red meat isisrichresponsible
in AA, the presencefor
of multiple
plasia and cancer
glands) [46].processes
Similarly, TXA2Sthrough
mRNA
biological
its cell surface
2
enzymes associated with AA metabolism might result in
and protein expression were higher in prostate carcinomas
increased synthesis of downstream lipid mediators. Several
compared to matched normal tissues. In contrast, epithelial
metabolites of AA, such as 5-HETE and 12-HETE, have
cells in non-tumoral glands displayed almost non-existent
already been studied widely for their roles in PCa [39–42].
TXA2S and TP expression [46]. The degree of TXA2S
Numerous studies demonstrate increased COX-2 mRNA
expression correlated with the severity of prostate carcinoma
and protein expression in PCa correlate with poor prognosis
lesions, with advanced stages and poorly differentiated forms
[43, 44]. TXA2 is derived from the COX product PGH2
having the highest expression levels [45, 46]. Moreover, a
significant association between the expression of COX-2/
and, as a consequence, both TXA2S and TP have long been
TXA2S/TP and higher Gleason score/pathologic stage of the
hypothesized to have a possible role in prostate cancer
progression.
tumors was observed [46]. Within the cancer tissue,
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receptor TP. Previous studies have shown that activation of TP by TXA2 or its stable
synthetic analog, U46619, will result in platelet aggregation [50], contraction of vascular
smooth muscle cells [60] or release of prostacyclin from endothelial cells [61]. Ligation
of TP by TXA2 can evoke the activation of multiple downstream pathways including
phospholipase C activation and a subsequent rise in the intracellular Ca2+
concentration, leading to vasoconstriction and platelet aggregation [48, 57]. TXA2 has
been implicated in the pathology of a variety of cardiovascular diseases, including
atherosclerosis [62], stenosis after vascular injury [63], and hypertension [64] [49].
Distribution of Thromboxane A2 Receptor (tissues and cells)
TP can be found in a large number of tissues, and cell types include platelets,
lung, vascular smooth muscle, endothelial cells, kidney, brain, spleen, thymus,
monocytes, uterus, and placenta [46, 57, 65].
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Table 1: Cells in which TP receptors have been identified based on ligand binding studies
[57, 65].

Thromboxane A2 Receptor–Ligand Interaction:
It was previously shown that the transmembrane (TM) region of TP contributes to its
ligand binding since point mutations of amino acids in the TM region resulted in
diminished ligand-binding activity [66]. The second extracellular loop (eL2) of TP is
important for ligand binging, especially amino acids Cys183 to Asp193 [67]. The NMR
study demonstrated that Val176, Leu185, Thr186 and Leu187 in eL2 of TP are putative
ligand contact points [68]. Point mutations within eL2 of TP indicated that Asp193 is a
key amino acid for ligand binding (both for binding to agonist and antagonist) [69]. This
study also reported that Phe184, Thr186 and Ser191 are key residues for antagonist
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binding [66]. Pharmaceutical companies have successfully designed TXA2 competitive
antagonists for TP that target this region thereby affecting its functional role.
Agonists and Antagonists:
TXA2 is very unstable in aqueous solution, where it is hydrolyzed with a half-life
of 30s to form the biologically inactive thromboxane B2 (TXB2) [36]. More stable
functional analogs have been synthesized because of the short half-life of TXA2 and
characterized. Notable agonists include U-46619 [70] [71] and I-BOP [72] [73]. The
antagonists include PTA2 [74], SQ-29,548 [75], Ramatoroban (Bay U3405) [76, 77], and
seratrodast [78, 79]. The failure of existing TXA2S inhibitors and TXA2 antagonists to
show robust clinical benefit in treatment of cardiovascular disorders has largely been
due to co-incident use of Nonsteroidal anti-inflammatory drugs (NSAIDs), such as
aspirin, as part of the standard of care. Conversely, current therapeutic regimens for
cancer incorporate few agents from this class making TXA2S/TP antagonism an
attractive target with potentially significant therapeutic benefit. Moreover, in contrast to
NSAIDs, TXA2S/TP inhibitors do not prevent other COX-derived anti-tumor products
with beneficial effects, such as PGI2, from being synthesized.
Thromboxane A2 Receptor and its Signal Transduction
Stimulation of TP receptors in platelets leads to an increase in intracellular free
calcium, activation of Phospholipase C, generation of IP3 and diacylglycerol, activation
of protein kinase C, stimulation of myosin light chain kinase and exposure of integrin
IIb/IIIa binding sites [53]. In platelets, stimulation of the TPα receptor isoform results in
an increase in cAMP formation. The same observation was made with CHO and COS 7 cells transfected with TPα [53, 58]. Ushikubi et al. showed that the presence of TPβ
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coupled to Gαi2 in reconstituted vesicles resulted in decreased cAMP formation [80].

Contribution of G proteins in TP Signaling:
TXA2 signaling through TPα and TPβ occurs when they couple with G proteins,
such as Gq, G11, G12, G13, G15, G16, Gi, Gs and Gh, which in turn regulate effectors
such as phospholipase C, guanine nucleotide exchange factor of the small G protein
Rho (RhoGEF) and adenyl cyclase (Figure 1.5) [57, 58, 66]. Activation of TP by TXA2
can evoke the activation of phospholipase C leading to phosphatidylinositol turnover
and a subsequent rise in the intracellular calcium ion concentration, which in turn leads
to vasoconstriction and platelet aggregation (Figure 1.5) [57, 66]. However signaling
through Gq and G12/13 appears most relevant to TP function [66]. Gq couples to
platelet TP receptors, as evidenced by increases in agonist stimulated GTPase activity
[66]. TP-mediated morphological changes in platelets are mainly dependent on G12/13.
Platelet aggregation by TXA2 is dependent on Gq (Figure 1.5) [81] [57-59].
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Figure 1.5: G protein coupling of thromboxane receptor and signal transduction
[66].
TP isoforms have both common and distinct signaling pathways depending on
the G protein subunits bound to their C-terminal tail. Therefore, differences in function
between TPα and TPβ must manifest due to the complement of G-proteins associated
with it [46].

One of the major differences between the two isoforms is the cAMP

pathway. When each TP isoform was expressed in CHO cells, IBOP, a TP agonist,
increased intracellular cyclic AMP levels in TPα-expressing cells, but decreased cyclic
AMP levels in TPβ expressing cells (Figure 1.5) [55]. These studies suggest that the
coupling of TPα with Gs-stimulating adenylyl cyclase and of TPβ with Gi-inhibiting
adenyl cyclase both induce changes in cyclic AMP levels, and this can be exploited [53].
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Furthermore, Gh functionally interacts with TPα, but not TPβ [82]. It has been also
shown that TPβ, but not TPα expression is required for the inhibition of vascular
endothelial growth factor (VEGF)-induced migration and angiogenesis [83], suggesting
that the downstream signaling pathways differ between TP isoforms [57-59].
Role of Thromboxanes in Cardiovascular Disorders:
Both TXA2 biosynthesis and thromboxane receptor (TP) expression is elevated in
numerous cardiovascular and inflammatory diseases [49, 56, 84, 85]. By signaling
through its receptors, TXA2 plays a very important role in the pathogenesis of acute
coronary artery syndrome, vessel remodeling, thrombosis, renal, pulmonary and
atherosclerotic cardiovascular diseases, primarily through its action as a potent
vasoconstrictor and an inducer of platelet aggregation and activation [56, 62, 79, 85-88].
Therefore, inhibition of TXA2S and TP has become central to the therapy of many
diseases including myocardial infarction, hypertension, stroke and renal dysfunction [8991]. Aspirin is the most common drug used to prevent TXA2 production. Other
thromboxane modulators which have been either approved for therapeutic use or under
clinical trials for the above mentioned diseases includes terbogrel [92], Ridogrel [93],
SQ-29548 [75], Ramatoroban (Bay U3405) [76, 77], and seratrodast [78, 79]. In recent
years, several studies revealed an additional functional role for both TXA2S and TP,
namely in cancer progression [46, 94-103].
Role of Thromboxanes in Cancer Progression:
Increased COX-2 expression has been described in a variety of diseases [33, 34]
and also documented in various cancers including pancreatic cancer [104], lung cancer
[105-107], breast cancer [108], colon cancer [109] and prostate cancer [106, 110-112].
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Though several reports have documented the antitumor effects of NSAIDs, it is not well
understood how COX promotes tumorigenesis and cancer progression. As TXA2 is a
downstream metabolite of the COX pathway, this has elicited interest as to whether
COX-2 actions are mediated by TXA2 signaling [113]. The eicosanoid products of the
COX pathway have dramatically different, sometimes contrasting or antagonizing,
biological activities [114-116]. Therefore, the actual profile of the downstream COX
metabolites is more relevant than the level of COX protein since the COX metabolites
such as TXA2 and PGI2 have diverse and opposing functions [46].
One of the first study to look into the role of downstream metabolites of COX,
such as TXA2 in cancer progression and metastasis was by Honn et al., where they had
shown inhibition of either TXA2S or TXA2 receptor reduced cancer metastasis in vivo
from tail vein injected B16a lung cancer cells. Inhibition of TXA2S also decreased tumor
cell proliferation and inhibits DNA synthesis in B16 melanoma cells [116, 117]. Several
years later, a study by Nie et al. in 2003, also indicated a functional role for TXA2S in
prostate cancer progression. Since then, there have been several reports indicating a
functional role for not only TXA2S but also for TP in several cancers that includes
breast, bladder, lung and colon cancer [46, 94-103]. Cancer progression involves
several key steps such as angiogenesis, cell survival, cell migration, cell invasion and
metastasis, and studies have shown that both TXA2S and TP play important roles in
one or more of these key process [46, 95, 96, 100, 118-120].
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Role of Thromboxanes in Prostate Cancer:
Nie et al. had shown that human PCa cells express TXA2S and that this enzyme
may contribute to PCa progression through modulation of cell motility [94]. As the
expression of COX-2 and COX-1 in prostate cancer has been reported previously, data
suggest that human PCa cells express functionally active TXA2S and that both COX-1
and COX-2 are essential for providing the substrate for TXA2S mediated TXA2
biosynthesis in PCa cells [94]. Increased TXA2S expression and activity in PCa cells
augmented cell migration, but had minimal effect on cell cycle progression or survival
[94]. Increased TXA2S expression and TXA2 biosynthesis in PCa cells highlighted
further a possible functional role for TP in PCa tissues, as the actions of TXA2 are
mediated by its interactions with TP receptors.
In a study conducted on tissue samples from 46 patients, with well-documented
histological and molecular data, increased TP, TXA2S and COX-2 expression were
observed in malignant tissues (High-Grade Prostatic Intraepithelial Neoplasia (HGPIN)
[46, 97]. Similarly, TXA2S mRNA and protein expression were higher in prostate
carcinomas compared to matched normal tissues [97]. In contrast, epithelial cells in
non-tumoral glands displayed almost no TXA2S or TP expression [46]. Moreover, a
significant association between the expression levels of COX-2, TXA2S, and TP and
higher Gleason score/pathologic stage of the tumors was observed [97]. Though this
study confirms that TP expression is higher in prostate cancer tissues, it did not identify
which isoform, TPα or TPβ, was predominantly expressed [46].
Tumor cell migration is an important step in the metastatic cascade, at which
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time the tumor cells leave the primary organ to enter the circulation, so as to colonize
distant tissues [121]. Prostate tumor progression involves several key steps including
cell survival, cell migration, cell invasion and metastasis, and studies have shown that
TXA2S or TP play a key role in either one of these processes [46]. Rho GTPases are
critical for the dynamic changes in cell shape and adhesion that drive cell migration. Nie
and colleagues demonstrated that the TXA2-TP signaling axis regulated cell migration
and cytoskeleton reorganization by promoting Rho-A activation [101]. Recent studies
have indicated that the Gα12 family of heterotrimeric G proteins (Gα12 and Gα13) is upregulated in PCa and that activation of Gα12 signaling, through a Rho-dependent
pathway, promotes PCa cell invasion. Also Gα12 signaling via Rho is required for
TXA2-stimulated invasion of PCa cells [122]. Therefore, as TP is known to couple to the
Gα12 family of heterotrimeric G-proteins, the up-regulation of both TP and Gα12 in PCa
suggests a possible role for TP in driving the cell migration and invasion observed in
high grade PCa.
There is also a novel constitutive interaction between TPα and TPβ with the
Protein kinase C-related kinases (PRK1) [123]. PRK1 is a RhoA effector that has been
widely implicated in androgen-associated PCa and ovarian serous carcinomas [123]. It
was established that PRK1 directly interacts with endogenously expressed TPα and
TPβ in both PC3 and LNCaP cells, and that disruption of PRK1 by siRNA substantially
impairs cell migration in response to TXA2 agonist U46619 in these cells [123]. These
findings are all suggestive of a functional role of TP receptor in cell migration in prostate
cancer [46].
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Crosstalk between Thromboxane and EGFR Signaling Pathways:
Mitogen-activated protein kinases (MAPK) play a central role in regulating cell
growth and differentiation. The activation of MAPK may result from stimulation of either
Receptor Tyrosine Kinases (RTK), which possess intrinsic tyrosine kinase activity, or GProtein-Coupled Receptors (GPCR) [124, 125]. The signaling pathways that link
GPCRs to MAPK involve both receptor and non-receptor tyrosine kinases as well as
Protein Kinase C (PKC) [126]. The Epidermal Growth Factor Receptor (EGFR) tyrosine
kinase as an essential link in the GPCR-mediated MAPK activation in Rat-1 fibroblasts,
HaCaT keratinocytes, primary mouse astrocytes, and COS-7 cells [127] [128, 129].
Studies also have shown that TP-mediated activation of MAPK signaling involves EGFR
by two possible mechanisms: Ligand-Independent (Src kinase-dependent) [127], and
Ligand-dependent (shedding of EGFR ligands) [130].
Transactivation of EGFR by TP receptor in a Ligand Independent Manner:
Gao et al. have shown that EGFR plays an essential role in the TP-mediated
MAPK activation in a ligand-independent manner. Activation of the Gq-coupled TP
receptor by the TXA2 mimetic IBOP in ECV304 cells (bladder cancer cell-line) was
found to induce ERK phosphorylation through tyrosine phosphorylation of EGFR in an
Src dependent manner (Figure 1.6) [127]. Tyrosine kinases of the Src family are
involved in mediating both the tyrosine phosphorylation of EGFR, and MAPK activation
from both Gq and Gi coupled receptors [127] [124, 125]. Furthermore, TP receptor
activation also increases Src kinase activity, which is blocked by Src Inhibitor PP1, but
not by AG1478, indicating that Src activation occurs before phosphorylation of EGFR
[127].

22

Figure 1.6: Activation of MAPK pathways by TP receptor involves transactivation of
EGFR in a Src kinase-dependent manner. A proposed model by Gao et al., suggests that
stimulation of TPα and TPβ by TXA2 leads to phosphorylation of ERK (ERK-P), and involves
transactivation of EGFR in a Src-kinase-dependent manner in TPα or TPβ-transfected cells
[127].

TP receptor mediated Transactivation of EGFR through the shedding of EGFR
Ligands:
The work of Galet et al. has shown the existence of an additional mechanism by
which TXA2 stimulation of TPα and TPβ in human aortic smooth muscle cells (hASMC)
cells leads to EGFR transactivation resulting in phosphorylation of ERK1/2 in a ligand
dependent manner. Transactivation of EGFR is dependent on the cleavage of proHeparin-binding EGF-like growth factor (HB-EGF) by matrix metallo proteinase (MMPs)
in response to TP receptor stimulation thereby allowing the binding of HB-EGF to its
receptor [126]. A broad spectrum inhibitor of MMPs, i.e. BB2516 decreased ERK and
EGFR phosphorylation in TPα or TPβ-transfected cells indicating the important role of
MMPs in TP-mediated EGFR transactivation (Figure-1.7) [126]. They also demonstrated
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that both TP isoforms activated ERK phosphorylation in an Src-kinase-dependent
manner in HEK293 cells. This confirms the existence of both ligand-dependent and
ligand-independent mechanisms of EGFR transactivation [126].

Figure 1.7: Crosstalk between Thromboxane and EGFR signaling by shedding of EGFR
ligands by MMPs. A proposed model by Galet et al., suggests that stimulation of TPα and TPβ
by TXA2 results transactivation of EGFR that is dependent on the cleavage of pro-HB-EGF by
extracellular MMPs thereby freeing HB-EGF to bind to its receptor [126].

In another study by Uchiyama et al. TP-mediated EGFR transactivation is partially
caused by shedding of EGFR ligands such as HB-EGF, which involves furin and ADAM
via novel types of PKCs (PKC-δ and PKC-ε) through Gαq/11 proteins in an extracellular
Ca2+-dependent manner [130]. Activation of TP activated the EGFR pathway by Srcdependent phosphorylation, and also activates EGFR by causing shedding of EGFR
ligands. These studies strengthen further the idea that TP receptor mediates EGFR
signaling.
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EGFR Family of Receptor tyrosine Kinases:
The EGFR family of RTKs consists of four members: EGFR/ErbB1, HER2/ErbB2,
HER3/ErbB3 and HER4/ErbB4 [131-138]. All EGFR family members share a similar
structure that consists of three regions: an extracellular ligand-binding domain, a single
trans membrane segment, and a large intracellular domain with protein kinase activity
(Figure-1.8) [139-144]. Upon activation by a number of EGF-like growth factor ligands,
ErbB receptors form homo or heterodimeric complexes that, which leads to the
autophosphorylation of cytoplasmic tyrosine residues in the kinase domain. This leads
to activation of down-stream signaling cascades, such as the Ras activated MAPK
pathway, and the phosphoinositide 3-kinase (PI3-K)/Akt pathway (Figure-1.8) [139-145].
ErbB receptors regulate multiple cellular responses, including cell proliferation,
survival, migration, and differentiation [146]. EGFR and ErbB4 can homodimerize when
bound to ligands, or heterodimerize with any of the other ErbB receptors, with ErbB2
being the preferred heterodimeric partner [147]. ErbB2 and ErbB3 each require
heterodimerization in order to transduce signals, because ErbB3 does not have an
intrinsic kinase, while ErbB2 is not bound by any known ligand (Figure-1.8) [147]. Hence
ErbB2 constitutively exists in the active conformation state. Therefore, it is always
available for dimerization with other EGFR family members [147]. ErbB signaling is
important for normal biological function, but unregulated signaling by EGFR and ErbB2
has been shown to contribute to cancer progression [139-144]. Members of the EGFR
family have frequently been implicated in various forms of human cancers and serve
both as prognostic markers and as therapeutic targets [139-144].
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Figure 1.8: Members of Epidermal Growth Factor Receptor (EGFR) Family: The ErbB
receptor family consists of four closely related type 1 transmembrane tyrosine kinase receptors,
EGFR, ErbB2, ErbB3, and ErbB4. EGFR and ErbB4 have active tyrosine kinase domains and
known ligands. ErbB3 can utilize several neuregulins as ligands, but lacks tyrosine kinase
activity. By contrast, ErbB2 possesses an active tyrosine kinase domain, but no ligand has been
identified [148].

Epidermal Growth Factor Receptor:
ErbB1 was the first RTK to be sequenced by Ullrich et al. [22]. EGFR is a
170 kDa transmembrane glycoprotein that is present on all epithelial and stromal cells
as well as on select glial and smooth muscle cells, though not on hematopoietic cells
[131, 141, 143]. EGFR can be activated by binding to growth factors of the EGF-family
that are produced by the same cells that express EGFR (autocrine secretion) or by
surrounding cells (paracrine secretion) [139, 143]. Upon binding of an extracellular
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ligand, the receptor transforms the inactive monomers into homodimers that activate its
intracellular tyrosine kinase domain and autophosphorylate its C-terminal tyrosine
residues. This stabilizes the active receptor conformation and creates phosphotyrosinedocking sites for proteins that transduce signals within the cell leading to activation of
several downstream signaling pathways (Figure-1.9)[131, 141, 143].
The EGFR homodimer possesses multiple sites of tyrosine phosphorylation and
couples to multiple downstream signaling effectors (Figure-1.9) [137, 140]. EGFR is
most often upregulated in a wide variety of human tumors such as bladder, breast, head
and neck, kidney, non-small cell lung, and prostate cancer, and is associated with
advanced disease and poor clinical prognosis [141, 146, 149, 150]. Studies of various
tumors have revealed that many express either EGFR or one of its common ligands,
such as the epidermal growth factor (EGF), Amphiregulin (AREG) and transforming
growth factor-α (TGFα). Some tumor cells express both the receptor and one of the
ligands [142, 144, 150]. Activation of EGFR by its ligands either in an autocrine or
paracrine manner has been shown to play an important role in prostate cancer
progression from localized PCa to metastatic disease [141, 146, 149, 150].
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Figure 1.9: EGFR tyrosine phosphorylation sites. A schematic representation of the
EGFR homodimer binding to its ligand is shown. Sites of cytoplasmic tyrosine (Y)
phosphorylation are indicated, as are cytosolic effector proteins that bind to these
phosphorylated tyrosine residues, and some of the effector signaling pathways [137,
140].
EGFR Ligands:
EGFR family members are activated by a large group of EGF-related growth
factors. Major EGF family members includes EGF, Amphiregulin (AREG), Epiregulin
(EREG), Transforming Growth Factor-α (TGF-α), Heparin-binding EGF-like growth
factor (HB-EGF), Betacellulin (BTC), Epigen and Neuregulins (NRG-1, NRG-2, NRG-3,
NRG-4) (Table-2) (Figure-1.8) [131, 132]. Common to all these growth factors is the
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2.3. ErbB mediated signaling
containing Src homology 2 (SH2) and phosphotyrosine binding
(Figure-1.8).
Signal transduction pathway
Table 1
ErbB tyrosine kinase receptors
The ErbB receptors and their cognate ligands
as Shc, Grb7, Grb2, Crk, Nck,
ErbB Receptors
EGFR
ErbB-2
ErbB-3
ErbB-4
the intracellular kinases Src a
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EGF
None
NRG 1
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phosphatases SHP1 and SHP2
TGF-α
NRG 2
NRG 2
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NRG 3
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NRG 4
MAPK pathway through either
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BTC
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Table.2: EGFR family of receptors and their ligands [154].
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Amphiregulin- an EGFR Ligand:
Amphiregulin (AREG) is a glycoprotein that is originally synthesized as a transmembrane precursor that undergoes ectodomain cleavage and is released as a
secreted protein [155, 156]. EGFR is believed to be the sole cell surface receptor for
AREG in epithelial cells, as AREG has not been shown to interact directly with other
members of the EGFR family such as ErbB2, ErbB3 and ErbB4 [157]. AREG binds
EGFR with a lower affinity than EGF, and induces receptor autophosphorylation and
downstream activation of the ERK signaling cascade [156, 158]. AREG mRNA is
expressed in many normal tissues including the placenta and ovary, where it is
abundant, as well as in the skin, testis, pancreas, spleen, kidney, lung, breast, and
gastrointestinal tract [159].
Several studies identified an active cAMP-Responsive Element (CRE) in the
AREG promoter [160, 161]. Other conserved response elements have been identified in
the human AREG promoter such as the Serum Responsive Element (SRE), the highly
conserved Specificity Protein-1 element (SP1), the WT-1 responsive element (WRE)
and the TATA box that all may have roles in regulation of AREG expression [156, 159,
162-166]. AREG can also be regulated by the EGFR itself, where activation of EGFR
leads to AREG expression in several cell types [155] [163, 165, 167]. For instance,
stimulation of EGFR in prostate stromal cells with mitogenic levels of EGF and HB-EGF
increased AREG mRNA expression more than 15-fold [166]. However, the specific
pathway leading from EGFR activation to AREG transcription has not been elucidated
prior to our study. Similar to EGFR, AREG also has been associated with several types
of human cancer [155, 158, 168, 169].
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Role of EGFR and their ligands in Prostate Cancer:
EGF family members and their membrane receptor, the EGFR are involved in the
pathogenesis of different tumors, including prostate cancer [170, 171]. Overexpression
of EGF family members and their receptors results in the progression of normal prostate
epithelial cells to a hyper proliferative cancer cell which is a key step in the multi-step
process of development of prostate cancer [171, 172]. Changes in gene expression of
growth factors and the corresponding changes in their receptor signaling pathways in
epithelial and stromal cells, contributes to enhancing tumor cell growth, survival,
migration and invasiveness [173, 174].
Studies have confirmed the important role played by the EGFR-driven autocrine
pathway in prostate cell growth, as it has been shown that prostate cancer cells express
the EGFR in vitro and in vivo, and that TGF or EGF are potent mitogens for prostate
cancer cells [154, 171]. Activated EGFR signaling may induce the stimulation of distinct
mitotic cascades, including those of the MAPK, PI3K/Akt, and Phospholipase-C (PC)
signaling pathways These in turn participate in the stimulation of proliferation, survival,
motility and invasion of PCa [174]. There are a number of mechanisms by which growth
factors of the EGF family, such as EGF, AREG, and TGF-α could contribute through
autocrine and paracrine mechanisms to prostate cancer cell growth and proliferation
[154, 158]. The enhanced expression of EGFR and its ligands, EGF, TGF-α, HB-EGF
and AREG, has been reported to correlate with high grades of PCa malignancies [158,
174].
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Role of Amphiregulin in Prostate Cancer:
AREG has been studied extensively for its role in breast cancer progression but
there have been few studies about its possible involvement in prostate cancer until now
[155, 168, 169]. Previous studies showed increased expression of AREG in both
androgen-dependent and independent PCa cell lines [157, 175].
One of the first hints of a possible role for AREG in PCa was in a study by Sehgal
et al. where it was shown that expression of AREG message and peptide in both
androgen-sensitive and androgen-independent prostate cancer cell-lines. Androgendependent PCa cells, such as LNCaP cells, do express amphiregulin mRNA and
peptide and this expression is elevated by androgenic stimulation [157]. Furthermore,
TGF-α stimulation of EGFR induces AREG expression in LNCaP cells suggesting the
mechanism of androgen-induced AREG expression is dependent on EGFR signaling.
Therefore androgenic effect of AREG synthesis may occur through androgen
upregulation of the EGFR expression [157].
Another study by Torring et al. has shown a selective upregulation of some
ligands belonging to the EGF family in androgen-independent prostate cancer cell lines.
Expression of mRNA for the ligands TGF-α, AREG, HB-EGF and EREG were increased
10 to 100 fold in androgen-independent cells and as compared to LNCaP and
PNT1A cells (Immortalized normal prostate epithelium) [175]. Similar results were
obtained when examining the protein levels as confirmed by ELISA [175].
Bostwick et al. analyzed prostate tissue sections from 93 prostate cancer
patients with pathologic stage T2N0M0 intermediate to high-grade (Gleason 6 and
higher, by design) and found that AREG expression in prostate increases progressively
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from benign epithelium to PIN and to prostate cancer. They were able to conclude that
increased expression of AREG might contribute to the development of prostatic
adenocarcinoma [158]. There have not been any studies looking further into the
mechanisms that result in increased AREG expression in both androgen-dependent and
independent cell lines. We have revealed herein a link between TP receptor signaling
and AREG in prostate cancer.
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Statement, Hypothesis and Specific aims:
Statement and Rationale:
Most of the work performed on TP receptor in prostate cancer thus far has
not focused on which of the two TP isoforms is indeed responsible for TP’s role in
prostate cancer. Previous studies have indicated different functional roles for both TP
isoforms [46, 83]. In lung cancer, TPα is thought to promote angiogenesis [176],
Whereas TPβ expression promotes increased proliferation, migration, and invasion in
bladder cancer cells. It is over-expressed in bladder cancer patients and associated with
poorer prognosis in those patients [99]. Expression status of TP isoforms is largely
uncharacterized in prostate cancer cells and tissues. One of the objectives of this study
is to profile TP isoform expression in prostate cancer cells and tissues, and determine
their functional contribution in prostate cancer.
As previous studies had shown that the TPα receptor isoform could promote
angiogenesis by up regulating VEGF in the lung cancer cell line A549 overexpressing
TPα receptor [176], we initially focused on whether TP signaling could promote VEGF
expression and subsequent angiogenesis in PCa cells.
Activation of endogenous TP in DU145 cells by TXA2 agonist led to an increase
in VEGF expression as expected, and revealed for the first time, a novel link to the
expression of amphiregulin (AREG) (1.5 Fold increase) in response to TP receptor
stimulation. AREG is a specific ligand of EGFR that activates its downstream signaling
pathways such as the MAP kinase pathways. We also looked at effect of TPα
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stimulation on the predominant ligand for EGFR namely EGF, and found no effects
(Figure- 1.10).

Figure 1.10: TP receptor activation in DU145 cells increased expression of AREG, a
ligand for EGFR. DU145 cells were serum starved and treated with IBOP 50nM (A) or ETOH
(B) for 16 hrs. Before the conditioned medium was collected to measure the impact of TP
receptor signaling on angiogenesis modulators. IBOP activation of TP receptor increased VEGF
expression (2 fold) as well as expression of AREG (1.5 fold).

TP receptor activation can lead to transactivation of EGFR through
phosphorylation in a both ligand dependent (HB-EGF) or ligand independent (Src
kinase) manner thereby implicating TP receptor as a regulatory point in the signaling
pathways that are stimulated by EGFR [127] [126]. Both TP and EGFR are highly
expressed in PCa and this has been shown to play a role in its progression [46, 101,
174]. Previous studies also have found increased expression of AREG in prostate cells
and tissues but the specific pathways leading to AREG expression have not yet been
elucidated [157, 158, 175]. Increased expression of AREG in response to TP stimulation
can lead to an alternate mechanism of EGFR activation in PCa cells. To the best of our
knowledge, this is the first study to explore the direct link between TP signaling and
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AREG expression in prostate cancer or any other cancer. As both TP receptor and
TXA2S enzyme are expressed in a wide range of cells and tissues including PCa
tissues and endothelial cells [46, 94, 101], increased expression of AREG in response
to TP receptor stimulation could lead to constitutive activation of EGFR signaling that
could increase tumor growth and progression. These findings led us to hypothesize that
the functional role of TP in PCa progression is mediated through activation of EGFR
signaling brought about by overexpression of its ligand, AREG.
Hypothesis
TP Receptor signaling plays a role in prostate cancer by promoting AREG activation of
EGFR signaling.
Specific Aims:
n Characterization of thromboxane receptor isoforms in PCa cell lines (in vitro) and
human tissues (in vivo).
n Determine whether stimulation of TP lead to AREG and EGFR overexpression
and activation of downstream signaling pathways.
n Determine the functional implications of TP activation in PCa invasion, tumor
growth and angiogenesis in vivo
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CHAPTER-2: MATERIALS AND METHODS
Materials and Reagents:
TXA2 agonist (I-BOP) and TXA2 antagonist (SQ29548, BM567) were purchased
from Cayman Chemicals (Ann Arbor, MI). PKA inhibitor H89, MEKK inhibitor U0126,
EGFR inhibitor AG1478, Src Inhibitor PP2 were obtained from Calbiochem (San Diego,
CA). EGFR inhibitor Gefitinib was kindly provided by the laboratory of Dr. Mustapha
Kandouz (Department of Pathology, Wayne State University). AMPK inhibitor
Compound-C was purchased from Millipore (Billerica, MA). Other chemicals were
obtained from Sigma–Aldrich (St. Louis, MO). RPMI-1640 culture medium and heatinactivated fetal bovine serum (FBS) were purchased from Hyclone (Thermo Fisher,
Rockford, IL). Human PCa cells PC3, DU145 and RWPE1 cells were supplied and
validated by the American Type Culture Collection (ATCC, Manassas, VA) and PC3M
Cells were obtained from Dr. Isaiah J. Fidler (University of Texas, MD Anderson Cancer
Center, Houston, TX). ECL Western blotting detection system was purchased from
Thermo Scientific (Rockford, IL) as were the horseradish peroxidase (HRP)-linked goat
anti-mouse and -rabbit IgGs. 	
  
Cell Culture:
PC3, DU145, PC3M and LNCaP cells were grown in RPMI (Hyclone
Laboratories, Inc., Logan, UT) containing 10% FBS at 37°C in 5% CO2 incubators.
RWPE-1 cells were grown in Keratinocyte Serum-Free Medium (K-SFM) that contained
two growth factors - 0.05 mg/ml BPE and 5 ng/ml EGF. Cell lines were frequently
monitored for mycoplasma contamination by mycoplasma PCR detection kit (Sigma–
Aldrich, St. Louis, MO).
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Generation of Stable Transfectants:
PC3 cells were transfected with plasmids encoding TPα (PC3-TPα), TPβ (PC3TPβ) or pcDNA 3.1 empty vectors (PC3-Neo) using the TransIT transfection reagent for
prostate (Mirus Bio LLC, Madison, WI) as per the manufacturer’s instructions. After 48h,
cells were grown for selection with G418 (400µg/ml) over two weeks. Clones expressing
high levels of TPα were pooled for total protein isolation as were empty vector control
cells (Neo). PC3-TPα and PC3-Neo cells were maintained in RPMI-1640 with 10% FBS
in the presence of 0.2 mg/ml of G418 (Geneticin, Life Technologies, Grand Island, NY).
Real time PCR was done with TP receptor isoform specific Taqman probes (Life
Technologies, Grand Island, NY) to validate stable transfectants.
Antibodies:
Rabbit polyclonal antibodies to human TPα and TPβ were kindly provided by Dr.
Anthony Ashton (University of Sydney, Sydney, Australia). Rabbit polyclonal antibodies
to Pan TP were purchased from Cayman Chemicals or GeneTex, Inc. (Irvine, CA).
Rabbit monoclonal antibody specific to EGFR, ErbB2, ErbB3, ErbB4, p-ERK, ERK, pSRC, SRC, p-AMPK, AMPK and CD31 were from Cell Signaling Technology, Inc.
(Danvers, MA). Antibody specific for beta-Actin was purchased from Millipore (Billerica,
MA). Horseradish peroxidase (HRP)-linked goat anti-mouse and rabbit IgG were
supplied by Thermo Fisher (Rockford, IL).
Primer Design and RT-PCR:
The gene specific primers for human TPα and TPβ and GAPDH were ordered
from Invitrogen. Thermo cycling PCR conditions: 95 °C for 2 min (Hot Start), (95°C for
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30s, 60°C for 30s, 72°C for 45s) for 40 cycles. Corresponding PCR products were run
on a 1.6% Agarose gel with Ethidium bromide and pictures of the gel were taken under
UV illumination using a Flour Chem Alpha-Imager Imaging system (Santa Clara, CA).
Table 3: List of Human specific primers used for RT-PCR
For-Forward
Rev-Reverse
Primer

Sequence

TP-For [54]

5'- TGTTTCCGGCCCACAAACATTA -3'

TP-Rev [52]

5'- GATACCCAGGTAGCGCTCTGA -3'

TP-For

5'- CCTTCCTGCTGAACACGGTCA -3'

TP-Rev

5'- GATATACACCCAGGGGTCCAG -3'

TPα-For [177]

5'- TTCCTGCTGAACACGGTC -3'

TPα-Rev [177]

5' -CGGAGCGCTGCGTGAGCT-3'

TP-For [99]

5’-ACGGAGAAGGAGCTGCTCATCT-3’

TPα-Rev [99]

5’-CCAGCCCCTGAATCCTCA-3’

TPβ-Rev [99]

5’-CAAAAGGAAGCAACTGTACCCC-3’

GAPDH-For

5’-GAGTCAACGGATTTGGTCGT-3’

GAPDH-Rev

5’-TTGATTTTGGAGGGATCTCG-3’

B-Actin-For

5’-GGACTTCGAGCAAGAGATGG-3’

B-Actin-Rev

5’-AGCATGTGTTGGCGTACAG-3’

Real-time PCR Taqman Gene Expression Assay:
Total RNA was isolated from sub confluent cells (60-80% confluent) using
Nucleospin-2 kit (Macherey-Nagel, Inc., Bethlehem, PA) following the manufacturer’s
protocol and reverse-transcribed into cDNA using the ABI High Capacity RT Kit (Life
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Technologies, Grand Island, NY). For real time detection of target gene expression,
TaqMan® Gene Expression Assays (Life Technologies, Grand Island, NY) were used.
Taqman Gene expression assays for TPα and TPβ were performed with custom
designed probes made with the help of ABI Primer Express software (Life Technologies,
Grand Island, NY). The GAPDH housekeeping gene internal control was a commercial
assay (Life Technologies, Grand Island, NY). PCR was performed using Applied
Biosystems 7500 Fast Real-Time PCR System in a total reaction mixture of 20 μl
containing 25 ng of cDNA, 1 x ABI TaqMan PCR Master Mix, and 1.25 μl of
probe/primers mixture (TaqMan® Gene Expression Assays). After denaturation at 95 °C
for 10 min, 40 cycles were performed at [95 °C for 10 s, 60 °C for 1 min] (universal
cycling conditions as per the manufacturer). The values for ΔΔCT were determined and
final relative expression analyses were performed using 2 –ΔΔCT (ΔΔCt = ΔCtsample –
ΔCtreference) as described previously [178].
SYBR Green Assay (AREG, EGF, EGFR, CD31, IL6, ErbB2, ErbB3, ErbB4):
Total RNA was isolated from sub confluent cells (70-80% confluent) (Nucleospin2, Macherey-Nagel, Inc., Bethlehem, PA) and reverse-transcribed into cDNA using the
ABI High Capacity RT Kit (Life Technologies, Grand Island, NY). Primers were designed
then synthesized by Invitrogen (Life Technologies, Grand Island, NY) or purchased from
Real Time Primers (Elkins Park, PA). Real- time PCR was performed in 10 ul reactions
using 96-well plates, 10-25 ng cDNA, and the 2X SYBR Green PCR Master Mix (Life
Technologies, Grand Island, NY). Reactions were performed in triplicate using the
Applied Biosystems ABI 7500 real-time PCR machine (Life Technologies, Grand Island,
NY).

40
Table 4: List of primers used for Real-time PCR SYBR Green assay
For-Forward

Rev-Reverse

Primer

Sequence

AREG-For [167]

5’-GTGGTGCTGTCGCTCTTGATA-3’

AREG-Rev [167]

5’-ACTCACAGGGGAAATCTCACT-3’

EGFR-For

5’-CTCAGCCACCCATATGTACC-3’

EGFR-Rev

5’-CGTCCATGTCTTCTTCATCC-3’

GAPDH-For

5’-GAGTCAACGGATTTGGTCGT-3’

GAPDH-Rev

5’-TTGATTTTGGAGGGATCTCG-3’

B-Actin-For

5’-GGACTTCGAGCAAGAGATGG-3’

B-Actin-Rev

5’-AGCATGTGTTGGCGTACAG-3’

VEGFA-For

5’-AGACACACCCACCCACATAC-3’

VEGFA-Rev

5’-TGCCAGAGCCTCTCATCTCC-3’

EGF-For [167]

5’-CGCAGGAAATGGGAATTCTA-3’

EGF-Rev [167]

5’-TCCACCACCAATTGCTCATA-3’

IL6 For

5’-AGCGCCTTCGGTCCAGTTGC-3’

IL6 Rev

5’-GTGGCTGTCTGTGTGGGGCG-3’

IL8 For

5’-TAGCAAAATTGAGGCCAAGG-3’

IL8 Rev

5’-AGCAGACTAGGGTTGCCAGA-3’

CD31 For

5’-ATTGCAGTGGTTATCATCGGAGTG-3’

CD31 Rev

5’-CTCGTTGTTGGAGTTCAGAAGTGG-3’

EREG-For [167]

5’- CTGCCTGGGTTTCCATCTTCT3 -3’

EREG-Rev [167]

5’- GCCATTCATGTCAGAGCTACACT -3’

ErbB2-For

5’-'CAGGCACCGCAGCTCATCTA-3’

ErbB2-Rev

5’-TCCCAGGTCACCATCAAATACATC-3’
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ErbB3-For

5’-CCCAGCATCTGAGCAAGGGTA-3’

ErbB3-Rev

5’-TTTAGGCGGGCATAATGGACA-3’

ErbB4-For

5’-TTTAGGCGGGCATAATGGACA-3’

ErbB4-Rev

5’-CCAGGTAGACATACCCAATCCAGTG-3’

SDS-PAGE and Western Blotting
Cells were extracted in cell lysis buffer, and proteins were loaded on 10% SDSPAGE gels and transferred onto nitro-cellulose membranes. Blots were then probed
with indicated antibodies and developed by enhanced chemi-luminescence (Pierce,
Thermo Fisher, Rockford, IL) according to the manufacturer’s instructions.
Tissue cDNA Arrays:

Commercial cDNA arrays containing representative sets of normal and
cancerous human tissue cDNAs (TissueScan™) were purchased from Origene
Technologies, Inc. (Rockville, MD) and used as per manufacturer’s instructions.
Cell Treatments:
For treatments, cells were plated in complete growth medium in 100 mm cell
culture dishes until they are 50-70% confluent. After 24-48 hrs, spent medium was
aspirated and replaced in serum-free medium for serum starvation overnight. Inhibitors
were dissolved either in DMSO or ethanol, diluted in serum free medium, and added to
the cells at appropriate concentrations for a given amount of time. Once the cells were
pre-treated at appropriate concentrations with the inhibitors (EGFR inhibitors- AG1478,
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gefitinib, AMPK inhibitor- Compound-C, PKA inhibitor-H89), TXA2 agonist I-BOP (50
nM) was dissolved in ethanol and added to the cells in serum-free medium for the
indicated times.

Measurement of cAMP:
Following treatment with I-BOP or antagonist, media samples from cultured cells
were collected and stored at -80o C for 1-2 weeks before its assayed. The cAMP
enzyme immunoassay (EIA) kit was purchased from Cayman Chemical (Ann Arbor, MI)
and used according to the manufacturer’s instructions.
Antibody Array:
The relative levels of expression of 55 angiogenesis-related proteins were
simultaneously detected using the commercial angiogenesis array (Catalog No:
ARY007) (R&D Systems, Minneapolis, MN). DU145 cells and PC3 transfectants were
cultured in 100 mm dishes, serum-starved overnight, and subsequently treated with
either IBOP (50nm) or ETOH (Vehicle) for 18hr as described.

Conditioned culture

medium was then screened by antibody array for angiogenesis related proteins as per
manufacturer’s instructions.
Modified Boyden Chamber Cell Invasion Assay
Cell invasion assays were done in modified Boyden chambers fitted with 8-µm
transwell filters as described [179]. PC3 parental or transfected cells were seeded in the
top of transwells of the 24 well plates at a density of (2x105 cells) / (0.5 ml of 1% BSA in
RPMI medium with ETOH, IBOP or SQ29548). Fetal bovine serum at 1% was used as a
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chemo attractant in the bottom chambers. After 18 h, residual, non-migrating cells on
the upper side of the membranes were removed using Kim-wipes, and the membranes
were fixed and stained according to manufacturer’s instructions for the Diff Quick
staining kit (IMEB, Inc., San Marcos, CA). Five fields of 100 cells, from random areas
were counted.
Animal Model and in vivo Studies:
All animal procedures were performed in accordance with the NIH and
institutional guidelines established for the Department of Laboratory Animal Research
(DLAR) at Wayne State University. Male aythymic NCr nude mice were purchased from
Taconic Farms, Inc. (Germantown, NY). A total of 2 X 106 PC3-TPα cells or PC3-Neo
control cells in 200 µl of HBSS were injected sub cutaneous (s.c.) into the right flank of
4-6-week-old male NCr nude mice (Six mice per group). Tumor measurements were
made using a vernier caliper, and tumor volume was calculated using the formula:
Volume = (width)2 x length/2 [180].
Mice were sacrificed six to seven weeks after injection, and tumors were
resected for further analysis [181]. Resected tumors were weighed and split into 10%
formalin

for

immunohistochemistry

and

in

Ambion’s

RNAlater

reagent

(Life

Technologies, Grand Island, NY) (frozen at -80oC) for subsequent RNA isolation.
Immunohistochemistry
Serial sections from formalin-fixed, paraffin-embedded (FFPE) tissues were
processed for immunohistochemistry analysis of CD31 and ki67 through core services
provided by University Pathology Research Services (Wayne State University and
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Barbara Ann Karmanos Cancer Institute, Detroit, MI)
Matrigel Implantation Assay for Tumor Cell-induced Angiogenesis.
The Matrigel implantation assay was performed as described by Ito et al. [182]
with the following modifications. Male SCID mice were purchased from Taconic Farms
(New York, NY). A total of 2 X 106 PC3-TPα cells or PC3-Neo control cells in 100 µl of
HBSS were mixed with 300 µl of Matrigel BME (Trevigen, Gaithersburg, MD) and
injected s.c. into the right flank of 4-6-week-old male SCID mice (six mice per group).
Mice were sacrificed 12 days after injection and dissected to expose the implants for
recording [183].
Measurement of AREG in Culture Media:
Cells were cultured in 6-well plates for measuring secreted AREG and other
angiogenic cytokines. Cells were plated at a density of 2 x 105 cells per well of a 6-well
plate. After 24 h, cells were serum starved overnight and then treated with TP agonists,
antagonists and chemical inhibitors. Following treatment, spent medium was collected
and the levels of AREG were determined using ELISA immunoassay kits from Ray
Biotech (Norcross, GA), based on manufacturer’s instructions.
Statistical Analysis:
Student's t test (two tailed) was used to analyze the difference between two
groups. Differential P values <0.05 were considered significant.
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CHAPTER-3: TPα-MEDIATED OVER EXPRESSION OF AMPHIREGULIN IS
MEDIATED BY AMP-ACTIVATED PROTEIN KINASE (AMPK)
Prostate cancer cells express TPα receptor:
Though the existence of two TP isoforms was known as early as 1994, most of
the earlier studies on TP did not distinguish the functional roles between the two
isoforms in cardiovascular disorders and cancer progression [46, 53, 58, 66]. However
recent findings suggest a novel role for TPβ in cancer progression especially in bladder
cancer [99]. TPα might play a role in tumor growth by promoting angiogenesis in lung
cancer [176], whereas TPβ expression promotes increased rate of proliferation,
migration, and invasion in bladder cancer cells and over-expressed in bladder cancer
patients and associated with poorer prognosis in those patients [99, 184]. In our earlier
studies, where we have shown TP receptor plays a role in cell motility by activating
Rho-A in prostate cancer was documented using antibodies/probes that bind the Nterminal domain that is common to both TP receptor isoforms. Expression status of TP
receptor isoforms and downstream signaling in response to TXA2 binding is largely
uncharacterized in prostate cancer cells and tissues. In this study, we first want to
determine which TP isoform is expressed in prostate cancer cell lines and tissues.
To evaluate the potential role of TP receptors in prostate cancer, prostate
epithelial cells and PCa cells were screened so as to identify which receptor isoforms
are present and to determine their expression levels.

RT-PCR (Figure 3.1) and

immunoblots (Figure 3.2) on whole cell extracts of the prostate cancer cell lines PC3,
DU145, PC3M and LNCaP, revealed that these PCa cells only express the TPα
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receptor isoform and not the TPβ receptor isoform. Real-time PCR data also indicated
that DU145 had the highest level of TPα expression (10-11 fold) followed by PC3 (3-4
fold) and PC3M (3 fold) compared to RWPE1 or PREC cells (Figure 3.3). TPα
expression in LNCaP cells was similar to RWPE1 cells. These data reveal that TPα
expression is higher in PCa cells compared to prostate epithelial cells, and that of the
cell lines tested, DU145 had the highest expression levels of this isoform.

Expression profile of TPα (mRNA) receptor in PCa cell-lines with TP isoform
specific Primer sets (RT-PCR)

A: TP isoform specific Primer set-1	
  

B: TP isoform specific Primer set-2
Figure 3.1: Screen for expression of TPα receptor in prostate cancer cell lines by
RT-PCR. Expression of TPR was verified in several PCa cell lines such as PC3, DU145, PC3M
and LNCaP cells and prostate epithelial cells (RWPE1) using RT-PCR. cDNA from PCa cell
lines was analyzed with two sets of isoform specific primers designed to detect: TPα, or TPβ (A,
B). PCR products were validated as TPα by sequencing. Non-RT samples (samples in which no
reverse transcriptase was added) were used as Negative controls. Recombinant TPα and TPβ
plasmids were used as positive controls (PC) for TP expression as indicated. Shown here is a
representative result from three independent experiments.
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A: Expression profile of TPα (protein) receptor in PCa cell-lines (Immunoblot)

	
  	
  	
  	
  

	
  	
  	
  	
  

	
  

B: Expression profile of TPβ (protein) receptor in PCa cell-lines (Immunoblot)

	
  	
  	
  	
  	
  	
  	
  

	
  

Figure 3.2: Screen for expression of TPα in prostate cancer cell lines by immunoblot.
Expression of TPR was verified in several PCa cell lines: PC3, DU145, PC3M and LNCaP cells
using Western blot. Total cell lysates prepared from these cell lines were probed with isoform
specific TP antibodies that can detect TPα (A) and TPβ (B). Recombinant TPα protein
expressed in SF-9 cells using baculovirus system was used as the positive control for TPα,
[185] and HUVEC cell lysates served as the positive control for TPβ. β-Actin served as a
loading control. The asterisks in A and B indicate non-specific bands. Shown here is a
representative result from three independent experiments.
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Figure 3.3: TPα expression was high in PCa cells compared to prostate epithelial cells.
Real-time PCR was done to compare the expression of TPα mRNA levels between PCa cell
lines (PC3, DU145, PC3M and LNCaP) and normal prostate epithelial cells (RWPE1, PREC).
Expression of TPα was higher among the PCa cells when compared with prostate epithelial
cells (RWPE1, PREC). Among the PCa cell lines, DU145 cells expressed the highest levels of
endogenous TPα mRNA expression. Values expressed represent the mean fold change ± SEM,
compared to PREC cells and is derived from three experiments normalized in each case to
GAPDH gene expression. Similar results were observed in a further two independent
experiments.

Functional status of TPα receptor expressed in PCa cells:
The multiplicity of effects by TXA2 stems from its receptor isoforms TPα and TPβ
coupling to several and distinct G-protein subunits leading to differences in function
between the two isoforms. TPα receptor isoform binds to Gs subunit thereby stimulating
adenylate cyclase, resulting in increased levels of the second messenger cAMP,
whereas TPβ receptor isoform binds to Gi subunit and inhibits adenylate cyclase,
thereby reducing cAMP levels [66]. Therefore, the differential response by two TP
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isoforms in terms of second messenger cAMP accumulation can be used as a tool to
confirm the expression and functional status of TPα expression in PCa cells.	
  Our data
demonstrates that cAMP levels are higher in DU145 cells compared to PC3, PC3M and
LNCaP cells which aligns with our earlier PCR and Immunoblotting results (Figure 3.4).
Although PC3 and PC3M cells exhibit expression of TPα protein and mRNA, the level of
cAMP accumulation in response to IBOP was lower in these cells compared to DU145
cells.

Figure 3.4: Endogenous TPα expression in PCa cells can elicit a functional response in
terms of second messenger. To verify whether TPα expression was enough to elicit a
functional response, PC3, DU145, PC3M and LNCaP cells were treated with vehicle (ETOH)
and agonist (IBOP) alone or pretreated with antagonist (SQ29548) before addition of agonist for
20min, and the effect on cAMP synthesis was measuredby cAMP specific Enzyme
ImmunoAssay (EIA). Results were DU145 had higher cAMP levels in response to IBOP when
compared with other PCa cells. The results shown are mean ± standard deviation of triplicate
wells, *p <0.05, **p <0.01; Student’s t test. This experiment was repeated at least three times
with similar results.
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Data-mining analysis confirms increased expression of TPR in Human PCa
tissues
TPα plays a critical role in tumor growth, angiogenesis, invasion and inflammation
[46, 176, 186, 187].

Moreover, expression of TXA2S, a rate-limiting enzyme for TXA2

biosynthesis, is significantly up regulated in prostate cancer tissues and correlates
positively with aggressiveness of the disease based on Gleason score [94]. In a study
by Dassasse et al., significant association between the expression levels of COX-2,
TXA2S, and TP and higher Gleason score/pathologic stage of the tumors was observed
[97]. Increased TP expression in PCa tissues documented in this study was done using
antibodies that bind to the common domain of TP, hence did not provide sufficient
information about which of the two TP isoforms is predominantly expressed [46].
To further examine the expression of TP isoform in prostate tumor tissues, we
have performed data mining analysis for TP expression in the cBio Cancer Genomics
Portal from Memorial Sloan-Kettering Cancer Center (MSKCC) that has published the
most comprehensive genomic prostate cancer database available to date [188, 189].
Several important observations resulted from these analyses, namely that TP receptor
expression appeared to be upregulated in 19% of prostate cancer patients studied
(n=85) (Figure 3.5), and was higher in PCa tissues compared to normal patient samples
(Figure 3.5). If the Z-score threshold is lowered to 1.5, then TP expression appeared to
be up regulated in 31% (n=26) of prostate cancer patients studied. However, the
MSKCC studies also do not discriminate between the TPα and TPβ isoforms as the
probes designed were for the common domain of TP [188].
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Figure 3.5: Database search using Memorial Sloan-Kettering Cancer Center
genomics database indicates that TPR expression is amplified in prostate carcinoma. TP
expression is upregulated in 19% (14 samples) of total PCa samples (n=85) tested by
microarray analysis with a Z-Score threshold of 2 that is statistically significant. Microarray
analysis for TP receptor was done with probes that were designed for the common domain of
TP and hence do not discriminate between the TPα and TPβ isoforms (n=85) [188]

TPα expression correlates positively with aggressiveness of prostate tumors.
All the work done so far showing increased expression of TP in PCa does not
discriminate between the two TP isoforms. We have shown that the PCa cell lines do
only express the TPα isoform and not the TPβ isoform. Since we know that TP is
overexpressed in PCa tissues based on our database analysis, we hypothesized that it
might be the TPα that is up regulated. Human PCa tissue was profiled for TPα utilizing
commercial cDNA expression arrays that included representative samples of both
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normal and prostate cancer tissues. Tissue cDNAs of each array were synthesized from
high quality total RNAs from pathologist-verified tissues, normalized and validated with
ß-actin in two sequential qPCR analyses. The manufacturer provided these with clinical
information and QC data. As there were no isoform-specific Taqman probes available
for TPα and TPβ through ABI, the arrays were screened with custom probes that were
designed using ABI Sequence detection software. Utilizing the accompanying clinical
information TPα expression levels were associated with grades of different tissue
samples based on Gleason scores [8] (Figure 3.6).
The TPα isoform was elevated in higher grade, more aggressive prostate cancer
seen in patients with a Gleason score greater than 7 (n = 9) versus Gleason 7 (n = 21)
or Gleason 6 and below (n = 11) and matched normal tissues (n=8) (Figure 3.6). Based
on the difference in primary and secondary patterns, the sum Gleason score 7 can be
depicted as GS (4+3) or GS (3+4), where the primary grade must be >50% of the total
cancer observed, and the secondary grade must be <50% but at least 5% of the
observed cancer [9]. Therefore, even within the same Gleason score differences in
gene expression are known to exist [9]. A significant finding from these data was that
TPα expression was elevated in GS7 (4+3) (n=7) compared to GS7 (3+4) (n=17), which
suggests that differences in TPα expression between primary and secondary patterns
(Figure 3.6) can potentially be exploited as a biomarker for discriminating GS7 subtypes
when making prognostic determinations. It also implicates TPα as a therapeutic target.
Collectively, the data-mining results and the data from qPCR analysis of human tissue
arrays make a strong case for the association of TPα expression with the
aggressiveness and progression of prostate tumors.
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Figure 3.6: TPα expression levels correlate with grades of different cancer tissues that
are classified based on its Gleason scores. Real-time PCR for TPα was done on Human
Prostate Cancer tissue cDNA arrays using custom designed TPα specific taqman assay probes.
The TPα isoform was elevated significantly in higher grade, more aggressive prostate cancer
seen in patients with a Gleason score greater than 7 (n=9). TPα expression is elevated
significantly in GS7 (4+3) (n=7) compared to GS7 (3+4) (n=17), suggesting stratification of TPα
expression between primary and secondary patterns. Values expressed represent the mean
fold change ± SEM, compared to Normal prostate tissues and is derived from two experiments
normalized in each case to β-Actin gene expression.

Overexpression of TPα receptor in PC3 cells:
To further understand whether TPα signaling mediates increased expression of
AREG, that might be responsible for its functional role in PCa, we used two different
Cell line models: 1. Wild-type DU145 cells (High endogenous TPα expression, Low
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TXA2S expression) 2. PC3 cells overexpressing TPα. PC3 cells do express
thromboxane synthase (TXA2S) and are a widely used model for in vivo studies. While
PC3 cells appeared to express endogenous TPα, the level of expression was
insufficient to elicit functional responses of TPα signaling such as cAMP activation and
phosphorylation of ERK compared to DU145 cells. In order to increase the expression
of TPα in PC3 cells to elicit better functional responses, we stably transfected TPα
plasmid in PC3 cells to examine the effect of TPα overexpression.
Stable trasfectants were generated and confirmed by Real-time PCR with TPαspecific taqman assay probes (Figure 3.7A), and by Western blotting (Figure 3.7B). TPα
transfected PC3 cells became responsive to 50 nM I-BOP induction of cAMP synthesis
(Figure 3.7C). Whereas, minimal activation of cAMP was measured in control PC3-Neo
cells (Figure 3.7C). These data demonstrated that the IBOP-responsive phenotype of
DU145 cells could be recapitulated in PC3 cells expressing ectopic TPα.
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3.7 B: Over-expression of TPα receptor (protein) in PC3 cells (Immunoblot)

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  

	
  

Figure 3.7: Over expression of TPα receptor in PC3 cells. PC3 cells were transfected with
TPα or TPβ expression plasmids, or empty vector (pcDNA 3.1) transfectants referred to as PC3TPα, PC3-TPβ and PC3-Neo were tested for over expression using: real-time PCR with
Taqman gene expression probes specific for TPα (A); Values expressed represent the mean
fold change ± SEM, compared to vector control and is derived from three experiments
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normalized in each case to GAPDH gene expression. Similar results were observed in a further
two independent experiments. Western blotting was done with antibodies specific for TPα and
platelets cell lysates were used as positive control for TPα (B). The asterisks in B indicate nonspecific bands (B) Immunoblotting for each protein was performed at least three times using
independently prepared lysates, and representative data from one such experiment are shown.
The functional status of TPα receptor was verified by measuring cAMP accumulation by cAMP
Enzyme Immunoassay (EIA)(C) The results shown are mean ± standard deviation of triplicate
wells, **p <0.01; Student’s t test. This experiment was repeated at least three times with similar
results.

Activation of TPα signaling promotes overexpression of AREG in PC3 cells over
expressing TPα:
Subsequently, PC3 prostate cancer cells expressing various levels of TPα were
employed to examine the role of TPα in prostate cancer progression. We treated PC3Neo cells, PC3-TPα transfectants with either ETOH (Vehicle) or TXA2 agonist IBOP for
16hrs and conditioned medium was collected for further analysis. Supernatants were
screened for growth factors such as AREG in response to TXA2 signaling using a
commercial antibody array (R&D Systems, Minneapolis, MN). In comparison to PC3Neo cells, PC3-TPα transfectants responded to IBOP activation of TPα by
overexpressing AREG (Figure 3.8 A-D).
To verify the findings of elevated levels of AREG expression in PC3-TPα
transfectants from the antibody array, ELISA for AREG was performed on the
conditioned medium collected earlier from PC3 transfectants. Our results confirmed a
higher secretion of AREG (5 fold) by the PC3-TPα cells in response to IBOP compared
to vector control cells (PC3-Neo) (Figure 3.8E). Pretreatment with TXA2 antagonist
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SQ29548 before addition of IBOP inhibited the increase in AREG expression and levels
were comparable to ETOH treated cells (Figure 3.8E). Using Real-time PCR, the effect
of TPα stimulation (IBOP) or inhibition (SQ29548) on AREG mRNA expression was
tested more directly. The results indicate that AREG mRNA levels increased 6 fold in
response to IBOP compared to ETOH treatment (Figure 3.8F). Pretreatment with TXA2
antagonist SQ29548 before addition of IBOP inhibited the increase in AREG mRNA and
levels were comparable to ETOH treated cells (Figure 3.8F).
To verify the findings from the TPα transfected cells, wild-type DU145 cells were
treated with either ETOH (Vehicle) or TXA2 agonist IBOP or TXA2 antagonist SQ29548
for 16hrs. Elevated levels of AREG expression both at the protein (ELISA) and mRNA
levels (1.5 fold) in response to IBOP were also confirmed by in DU145 cells (Figure 3.8
G, H). These findings proved that TPα does play a direct role in increased expression of
Amphiregulin, a ligand for EGFR in prostate cancer cells.
3.8 A-D: Effect of TPα stimulation by IBOP on AREG (protein) expression in
PC3 transfectants (Antibody Array)
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Figure 3.8: Activation of TPα in PC3 cells over expressing TPα increases AREG, a ligand
for EGFR. PC3-TPα and PC3-Neo cells were serum-starved overnight followed by treatment
with ETOH (A, C) or IBOP (B, D). Conditioned medium was collected and screened by an
angiogenesis antibody array. Activation of TPα by IBOP in PC3-TPα cells led to an increase in
AREG expression levels but had little effect on EGF expression levels. PC3-TPα and PC3-Neo
transfectants were serum-starved overnight and were treated either with ETOH or IBOP (50 nM)
only, or they were pretreated with SQ29548 (10 µM) for 30 min before addition of IBOP.
Conditioned medium was collected and cDNA isolated from the cell lysates. Data from Realtime PCR (F) and ELISA (E) also confirms the increase in expression of AREG mRNA and
protein expression in PC3-TPα cells treated with IBOP when compared with ETOH or SQ29548
treated cells. Similar results were obtained with parental DU145 cells when treated with IBOP
(G, H). Real-time PCR values expressed represent the mean fold change ± SEM, compared to
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vector control and are derived from three experiments normalized in each case to GAPDH gene
expression. Similar results were observed in a further two independent experiments. The ELISA
results shown are mean ± standard deviation of triplicate wells, *p <0.05, **p <0.01; Student’s t
test. This experiment was repeated at least three times with similar results

Activation of TPα signaling had little effect on EGF expression in PC3 cells over
expressing TPα:
We also looked at the effect of TPα receptor on EGF, which is the predominant
ligand for EGFR, and did not find any change in EGF levels (Figures 3.8 A, B, C, D). To
determine whether TPα receptor stimulation could lead to increased expression of EGF
mRNA, we did Real-time PCR on cDNA samples from PC3-TPα transfectants treated
with vehicle (ETOH), agonist (IBOP) or antagonist (SQ29548). We did not find any
change in EGF mRNA expression in response to IBOP by Real-time PCR in PC3-TPα
transfectants (Figure 3.9A). Similar results were obtained in parental DU145 cells that
express higher levels of endogenous TPα (Figure 3.9B). These results indicate that
activation of TPα by IBOP selectively upregulates AREG expression at the level of
protein and mRNA but has little effect on EGF expression.
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Figure 3.9: Activation of TPα in PC3-TPα transfectant cells over expressing had little
effect on expression of EGF, the predominant ligand for EGFR: PC3 transfectants (A) and
DU145 cells (B) were serum starved overnight and cells were treated with ETOH or IBOP (50
nM) only or pretreated with SQ29548 (10 µM) for 30m before addition of IBOP. After 16 hrs. of
treatment, cells were lysed in RNA lysis buffer for total RNA isolation. Expression of EGF mRNA
in PC3-TPα (A) and DU145 cells (B) was minimally affected by treatment with IBOP. Values
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expressed represent the mean fold change ± SEM, compared to vector control cells and is
derived from three experiments normalized in each case to GAPDH gene expression. Similar
results were observed in a further two independent experiments.

AREG produced through activation of TPα receptor is functional and can
phosphorylate EGFR in PC3 cells:
AREG selectively binds to EGFR, following dimerization of EGFR, which leads to
dimerization of the receptor itself as either a homodimer or as a heterodimer with other
EGFR family members. Subsequently EGFR undergoes phosphorylation at specific
tyrosine residues within the intracellular domain that in turn activates downstream
signaling pathways such as MAP kinase [ERK-1/2]. Therefore, we sought to determine
whether the AREG that was induced in response to TPα receptor stimulation in PC3
transfectants was functional. We assayed AREG from PC3-TPα conditioned medium for
its ability to bind EGFR and mediate phosphorylation at tyrosine residue (pY1068).
To test whether this led to subsequent activation of ERK1/2, we performed
following addback experiments. Conditioned medium was collected from PC3-Neo cells
or PC3-TPα transfectants treated with IBOP alone (PC3-TPα+IBOP, PC3-Neo+IBOP)
for 16hrs. To determine if TPα mediated AREG production made a difference in the
phosphorylation of EGFR or ERK1/2, we compared immunoblots of cells treated with
CM from PC3-TPα to that of CM from PC3-Neo cells. We also performed the addback
experiments in parental PC3 cells that have endogenous EGFR but have lower TPα
receptor levels. To avoid any trans activation of EGFR involving endogenous TPα
receptor, PC3 cells were pretreated with TXA2 antagonist SQ29548 or ETOH for 30
minutes before addition of IBOP-treated-conditioned medium collected from PC3-TPα
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transfectants. Whole cell lysates were prepared and subsequently analyzed for
phosphorylation of EGFR and downstream targets such as ERK1/2 (Figure 3.10).
Our results support an active role for TPα receptor driven AREG production that
leads to AREG activation of EGFR at pY1068 (Figure 3.10). Our results also support
that AREG in the conditioned medium collected from PC3-TPα cells not only binds to
EGFR leading to its phosphorylation but can activate downstream signaling pathways
such as MAP kinase pathway as evident by phosphorylation of ERK1/2 (Figure 3.10).
Therefore our studies reveal a novel means of indirect TPα receptor activation of EGFR
through the effects of TPα receptor on AREG.
3.10 Functional status of AREG secreted in response to TPα receptor stimulation
in the conditioned medium from PC3 transfectants (Immunoblot)
3.10 A: Effect of AREG on EGFR phosphorylation (Immunoblot)
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3.10 B: Effect of AREG on EGFR phosphorylation (Immunoblot)

	
  

3.10 C: Effect of AREG on MAPK activation (Immunoblot)
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3.10 D: Effect of AREG on MAPK activation (Immunoblot)

3.10 E: Effect of AREG on EGFR Phosphorylation – Loading control (Immunoblot)
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Figure 3.10: AREG secreted in response to TPα receptor activation is active and leads to
EGFR phosphorylation. PC3-TPα and PC3-Neo cells were serum-starved overnight and then
treated with IBOP only. Conditioned medium was collected and secreted AREG activity post
TPα stimulation was assayed. PC3 parental cells were serum-starved overnight and pretreated
with TXA2 antagonist SQ29548 or ETOH for 30 min. These were subsequently treated with the
conditioned medium collected from PC3 transfectants for 5min or 10min. Cell lysates were
probed by immunoblot with phospho-specific antibodies for EGFR (A) and ERK1/2 (C). Total
EGFR (B) and ERK1/2 (D) were used as loading controls for p-EGFR and p-ERK respectively.
Actin served as a protein loading control (E). AREG in the conditioned medium from PC3-TPα
cells stimulated increased phosphorylation of EGFR at pY1068 and ERK1/2 when compared to
the conditioned medium from PC3-Neo cells. These findings indicate that AREG produced in
response to activation of TPα is functional through binding of EGFR leading to its
phosphorylation and activation of MAPK pathways. Immunoblotting for each protein was
performed at least twice using independently prepared lysates, and representative data from
one such experiment are shown.

Activation of TPα signaling promotes overexpression of EGFR in PC3 cells over
expressing TPα:
After observing the relationship between TPα signaling and increased
AREG expression at the level of both protein and mRNA, we looked to see whether TPα
affected the expression of EGFR itself from PC3-TPα and PC3-Neo cells that were
treated with ETOH, IBOP and SQ29548. After 16 hr, cells were trypsinized and cell
pellets were divided into two tubes for protein and cDNA analysis respectively. Realtime PCR and immunoblot analyses revealed that EGFR mRNA and protein expression
was significantly elevated in PC3-TPα cells in response to IBOP when compared to the
vector control cells (PC3-Neo) (Figures 3.11 A, B). Pretreatment with TXA2 antagonist
SQ29548 before addition of IBOP reduced EGFR expression to the level in untreated
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cells, thereby confirming that TPα signaling also regulates EGFR expression in addition
to AREG (Figures 3.11 A, B).
We opted to corroborate the findings from PC3 transfectants by examining
parental cells that have naturally elevated levels of TPα. These were treated with either
ETOH (Vehicle) or TXA2 agonist IBOP or TXA2 antagonist SQ29548 for 16hr. DU145
cells stimulated with IBOP had a significant increase in EGFR mRNA (Figure 3.11C)
and protein levels (Figure 3.11D) compared to ETOH treated cells. Pretreatment with
SQ29548 prior to addition of IBOP reduced EGFR expression back to levels achieved
with ETOH alone (Fig 3.11 C, D). Collectively these data reveal that TPα activation with
IBOP in PC3-TPα transfectants as well as in parental DU145 cells stimulated AREG
production, and also its cognate receptor, EGFR. This demonstrates for the first time
that signaling events of the two receptors are coupled in prostate cancer.
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3.11 B: Effect of TPα stimulation by IBOP on EGFR (protein) expression in
PC3 transfectants (Immunoblot)
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3.11 D: Effect of TPα stimulation by IBOP on EGFR (protein) expression in
DU145 cells (Immunoblot)

Figure 3.11: Activation of TPα in PC3 cells over expressing TPα resulted in an increase of
EGFR. PC3-TPα, PC3-Neo and DU145 cells were serum starved overnight and were either
treated with ETOH, IBOP (50 nM) only or pretreated with SQ29548 (10 μM) for 30m before
addition of IBOP for 16 hr. After treatment, cells were trypsinized, centrifuged and cell pellets
were divided into two tubes for protein and cDNA analysis respectively. Data from Real-time

70
PCR reflects an increase in expression of EGFR mRNA expression in PC3-TPα cells treated
with IBOP (A) when compared with ETOH or SQ29548 treated cells. Results from the
immunoblotting suggest that activation of TPα by TXA2 mimetic IBOP in PC3-TPα cells resulted
in an increase of EGFR (B) Similar results were obtained with DU145 cells that have higher
endogenous TPα expression (C, D). Immunoblotting for each protein was performed at least
three times using independently prepared lysates, and representative data from one such
experiment is shown. Real-time PCR Values expressed represent the mean fold change ± SEM,
compared to ETOH treated vector control cells and is derived from three experiments
normalized in each case to GAPDH gene expression. Similar results were observed in a further
two independent experiments.

Activation of TPα signaling had little effect on expression of ErbB2, ErbB3 and
ErbB4 in PC3 cells over expressing TPα
As EGFR was over expressed in response to TPα stimulation, we then sought to
determine whether TPα could affect a change in expression of other EGFR family
members such as ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4) that can indeed
dimerize with EGFR. PC3 transfectants cells were serum-starved overnight and treated
with ETOH, IBOP alone or pretreated with SQ29548 for 30 min followed by addition of
IBOP for 16 hr. After treatment, cells were trypsinized, centrifuged and cell pellets were
divided into two tubes for protein and cDNA analysis respectively. Real-time PCR
(Figures 3.12 A, B, C) and Immunoblot analyses (Figure 3.12 D) revealed that there
was very little effect on ErbB2, ErbB3 and ErbB4 mRNA and protein expression in PC3TPα cells in response to IBOP when compared to the vector control cells (PC3-Neo).
Pretreatment with TXA2 antagonist SQ29548 before addition of IBOP, did not affect the
expression of EGFR family members (Figures 3.12A, B, C, D). These studies clearly
demonstrate that TPα activation with IBOP in PC3-TPα transfectants resulted in
increased expression of EGFR but not other EGFR family members.
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3.12 D: Immunoblot: Effect of IBOP on ErbB2, ErbB3, ErbB4 expression
in PC3 transfectants
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Figure 3.12: TPα activation in PC3-TPα transfectants had little effect on expression of
other EGFR Family members, ErbB2, ErbB3 and ErbB4. PC3-TPα and PC3-Neo cells were
serum-starved overnight and were treated either with ETOH, IBOP (50 nM), only or pretreated
with SQ29548 (10 µM) for 30m before addition of IBOP for 16 hr. After treatment, cells were
trypsinized, centrifuged and cell pellets were divided into two tubes for both protein and total
RNA isolation. Real-time PCR data indicate that activation of TPα by IBOP in PC3-TPα cells
had little effect on expression of ErbB2, ErbB3 and ErbB4 mRNA (A, B, C) when compared with
ETOH or SQ29548-treated cells. Additionally results from the immunoblotting suggest that
activation of TPα by TXA2 mimetic IBOP in PC3-TPα cells had little effect on expression of other
EGFR family members, ErbB2, ErbB3 and ErbB4 (D). Real-time PCR Values expressed
represent the mean fold change ± SEM, compared to vector control cells and is derived from
three experiments normalized in each case to GAPDH gene expression. Similar results were
observed in a further two independent experiments. Immunoblotting for each protein was
performed at least twice using independently prepared lysates, and representative data from
one such experiment are shown.

75
EGFR upregulated as a result of TPα activation is functional and actively signals
in PC3 transfectant cells:
As our data from real-time PCR and Immunoblot showed that PC3 cells do
express EGFR but exhibited differential expression of other EGFR family members in
PC3 transfectant cells. Therefore, we wanted to confirm, whether the EGFR expressed
in response to TPα stimulation in PC3 transfectants cells was functional. To test the
functionality of EGFR produced by PC3-TPα transfectants in response to TPα
stimulation, we treated PC3-Neo and PC3-TPα cells with either EGF or vehicle (PBS)
for 5 min. Total protein was harvested from these cells and assayed for the levels of pEGFR, EGFR, p-ERK and ERK by Western blotting (Figure 3.13).
As evident on Figure 3.13, treatment of PC3-Neo and PC3-TPα cells with EGF
resulted in increased phosphorylation of EGFR at pY1068, which is an indication of
ligand dependent phosphorylation and a functional receptor (Figure 3.13). Furthermore,
signaling pathways that are downstream of EGFR such as MAP kinase were activated
as evident by phosphorylation of ERK1/2 (Figure 3.13).
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3.13 Functional status of EGFR expressed in PC3 transfectants (Immunoblot)	
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Figure 3.13: Add-back experiment proving that EGFR expressed in PC3 transfectants is
functional. PC3-TPα and PC3-Neo cells were serum-starved overnight and then treated with
either PBS (vehicle) or EGF for 5min and cells were lysed, and immunoblotted with phosphospecific antibodies for EGFR (A) and ERK1/2 (C). Total EGFR (B) and ERK1/2 (D) were used
as a loading control for p-EGFR and pERK1/2 respectively. Actin (E) served as a protein
loading control. Our data indicate that EGF treated PC3-Neo and PC3-TPα cells showed
increased phosphorylation of EGFR and ERK1/2 concluding that EGFR expressed in both PC3Neo and PC3-TPα cells is functional. Immunoblotting for each protein was performed at least
twice using independently prepared lysates, and representative data from one such experiment
are shown.

Upregulation of AREG by TPα is not dependent on the PKA pathway:
The molecular mechanisms involved in the regulation of AREG expression by
TPα receptor are largely unknown. Our studies show that activation of TPα by IBOP in
PC3-TPα cells results in increased levels of the second messenger cAMP (Figure 3.4).
Recent studies have shown that the cAMP pathway can induce AREG in T cells as well
as in cells of nonlymphoid origin such as H295R (adrenal) and MCF-7 cells (breast
cancer) [160]. As it is known that one of the downstream targets of cAMP is PKA, we
wondered whether PKA might be involved in the expression of AREG.
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To look into the role of PKA and EGFR in TPα mediated AREG expression, we
pretreated PC3-TPα and PC3-Neo cells with PKA inhibitor H89 (20 μM) for 30 min
before incubation with TXA2 agonist IBOP for 18 hr. Following incubation, total RNA was
isolated from these cells and processed for Real-time PCR analysis of AREG mRNA
expression. Treatment with the PKA inhibitor H89 had no effect on AREG expression
mediated by activation of TPα receptor (Figure 3.14). This suggests that upregulation of
AREG by TPα is not dependent on the PKA pathway.
	
  

Figure 3.14: Upregulation of AREG by TPα is not dependent on the PKA pathway. PC3TPα and PC3-Neo transfectants were serum-starved overnight and were treated either with
ETOH, IBOP (50 nM) only, or pretreated with SQ29548 (10 µM) and H89 before addition of
IBOP for 16 hr. Data from Real-time PCR confirms that PKA inhibitor H89 had no effect on
AREG expression mediated by activation of TPα receptor in PC3-TPα cells when compared to
IBOP treated cells alone. Values expressed represent the mean fold change ± SEM, compared
to ETOH treated vector control cells and is derived from three experiments normalized in each
case to GAPDH gene expression. Similar results were observed in a further two independent
experiments.

79
Upregulation of AREG by TPα is dependent on the AMPK pathway.
Though studies have shown that AREG can be induced by the cAMP pathway in
in T cells as well as in cells of nonlymphoid origin such as H295R (adrenal) and MCF-7
cells (breast cancer) [160], our Real-time PCR data nonetheless showed that
pretreatment of PC3 transfectant cells with PKA inhibitor (downstream mediator of
cAMP) had no effect on expression of AREG, which suggested an alternate pathway
involving cAMP [160]. We wondered whether AMP-activated protein kinase (AMPK), an
alternate cAMP-signaling pathway is involved in the overexpression of AREG mediated
by stimulation of TPα receptor. As we have previously shown that activation of TPα
does increase cAMP levels, the relationship between thromboxane signaling, AMPK
and AREG was studied in TPα overexpressing PC3 cells. AMPK is a sensor for
changes in cellular energy state and is activated by an increase in the intracellular AMPto-ATP ratios in response to various stresses such as hypoxia, oxidative stress and
glucose deprivation [190-194]. Activation of AMPK requires phosphorylation of Thr172
in the activation loop of the α subunit by at least 2 upstream kinases, LKB1 and
Ca2+/calmodulin-dependent kinase kinase (CaMKK)-β [190-194].
TPα activation increases cAMP levels, as well as intracellular Ca2+ concentration.
Therefore we investigated the role of AMPK in TPα mediated AREG expression.
Previous studies by Zhang et al. had shown that TP activates the AMPK in vascular
smooth muscle cells via hydrogen peroxide [190].
Apart from cAMP being a regulator of AREG expression, studies have shown
that AREG also can be regulated by the EGFR itself and activation of EGFR leads to
AREG expression in several cell types [155, 157, 160, 166]. As it is known that EGFR
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can directly regulate AREG through EGFR-AREG autocrine loop, we questioned
whether this might be true in TPα mediated AREG upregulation [155]
To investigate whether TPα mediates AREG upregulation via the AMPK
pathway and to identify the role-played by EGFR in the expression of AREG, we
pretreated the PC3-TPα and PC3-Neo cells with the AMPK inhibitor Compound-C (20
μM) and EGFR inhibitors Gefitinib (20 μM) or AG1478 (5 μM) for 30 min before
incubation with TXA2 agonist IBOP for 18hrs. Gefitinib or AG1478 is an EGFR inhibitor
that binds to the tyrosine kinase domain and inhibits downstream EGFR signaling.
Following incubation, total RNA was isolated from these cells converted to cDNA and
Real-time PCR was done for AREG mRNA expression. The amount of AREG transcript
was estimated based on the Relative quantification method. Treatment with the AMPK
inhibitor Compound-C in PC3-TPα cells led to an decrease in the level of AREG as
shown in Figure 3.15A to the levels comparable to ETOH or SQ29548 treated cells.
This suggests that TPα upregulates AREG mRNA levels through cAMP by stimulating
the AMPK pathway (Figure 3.15A).
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Figure 3.15: Upregulation of AREG by TPα is dependent on AMPK pathway. PC3-TPα and
PC3-Neo transfectants were serum starved overnight and were either treated with ETOH, IBOP
50nM only or pretreated with SQ29548 (10 µM), Gefitinib (20 μM), AG1478 (5 μM) and
Compound-C (20 µM) for 30 min before incubation with IBOP for 18 hr. AMPK inhibitor
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Compound-C strongly affects AREG expression mediated by TPα in PC3-TPα cells (A). EGFR
inhibitors, Gefitinib and AG1478 reduced expression of AREG, mediated by TPα in PC3-TPα
cells to a lesser extent than compound-C (A). Values expressed represent the mean fold
change ± SEM, compared to vehicle treated vector control and is derived from three
experiments normalized in each case to GAPDH gene expression. Data from ELISA supports
the Real-time PCR data, that inhibition of the AMPK pathway reduces levels of AREG
expression mediated by TPα activation (B). Similar results were observed in a further two
independent experiments. The ELISA results shown are mean ± standard deviation of
triplicate wells, *p <0.05, **p <0.01; Student’s t test. This experiment was repeated at least three
times with similar results.

To verify our findings from Real-time PCR at the protein level, conditioned media
was collected from PC3-TPα and PC3-Neo cells treated with AMPK inhibitor or EGFR
inhibitors and the levels of AREG were assayed by ELISA and normalized to cell
number. We observed that, Compound-C decreased AREG secretion from PC3-TPα
cells when compared to IBOP treated cells (Fig 3.15B). Also treatment with EGFR
inhibitors had a partial inhibition on expression of AREG mediated by TPα when
compared with AMPK inhibitor (Fig 3.15B). The reduction of AREG secretion in PC3TPα overexpressing cells upon treatment with AMPK inhibitor suggests that the AMPK
pathway is required for AREG secretion in these cells (Fig 3.15B). From these
experiments, it is evident that AMPK pathway plays a key role in IBOP mediated
increase in AREG secretion in the TPα overexpressing cells.
Activation of TPα signaling results in increased PCa cell invasion.
To determine whether TPα activity in PC3 cells translates to a more invasive
phenotype and AREG does play a role in it, a modified Boyden chamber assay was
performed where transwell chambers were coated with Matrigel, and PC3-TPα or PC3Neo cells were treated with either ETOH (Vehicle), IBOP (agonist), or SQ29548
(antagonist). Of all the treatments, only IBOP increased the invasiveness PC3-TPα cells
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(Figures 3.16A, 3.16B). Similar results were obtained with DU145 cells that have higher
endogenous TPα levels. Treatment of DU145 cells with IBOP also increased the
invasive capacity of the cells when compared to treatment with either ETOH or
pretreatment with the antagonist SQ29548 (Figure 3.16C). Invasiveness of PC3-TPα
and PC3-Neo cells were similar in response to 5% FBS stimulation.
Studies have shown that EGFR signaling pathway plays an important role in cell
migration and invasion [195, 196], we wondered whether AREG or EGFR might be
involved in increasing the invasive capacity of the cells mediated by TPα. Over
expression of AREG mediated by TPα in PCa cells can then activate EGFR and then
activate signaling pathways that result in increasing the invasive nature of these cells.
To study whether AREG or EGFR has a role to play in it, we pretreated PC3-TPα and
PC3-Neo cells with EGFR inhibitor gefitinib (25 μM) or AMPK inhibitor-Compound-C (20
μM) for 30min, before incubation with IBOP for 18 hr and cells were fixed and pictures
of invasive cells were taken with a Nikon TE200 inverted microscope (Figure 3.16A, C,).
Gefitinib is an EGFR inhibitor that binds to its tyrosine kinase domain and inhibits
signaling through the EGFR pathway and Compound-C is an AMPK inhibitor. Binding of
gefitinib to EGFR also will prevent AREG to activate EGFR and thereby affecting its role
in cellular invasion whereas AMPK inhibitor should affect the overexpression of AREG
mediated by TPα receptor. Treatment with Gefitinib or AMPK inhibitor did reduce the
invasiveness of these cells, induced by IBOP, indicating that EGFR signaling is involved
in TPα mediated invasion (Figure 3.16A, B, C, D). Similar results were obtained with
DU145 cells that have higher endogenous TPα levels when treated with EGFR inhibitor
gefitinib or AMPK inhibitor (Figure 3.16E, F).
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3.16 A: Effect of EGFR and AMPK inhibitors on TPα mediated cell invasion in
PC3-TPα cells (Modified Boyden chamber assay)
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3.16 C: Effect of EGFR and AMPK inhibitors on TPα mediated cell invasion in
PC3-Neo cells (Modified Boyden chamber assay)
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3.16 E: Effect of EGFR and AMPK inhibitors on TPα mediated cell invasion in
parental DU145 cells (Modified Boyden chamber assay)

Figure 3.16: Activation of TPα signaling by IBOP stimulation results in increased
invasiveness of PCa. Modified Boyden chamber assay was done where transwell chambers
were coated with matrigel and PC3-TPα and PC3-Neo cells that were serum starved overnight
and were either treated with ETOH, IBOP (50 nM) only or pretreated with SQ29548 (10 μM)
Gefitinib (20 μM) or AMPK inhibitor Compound-C (20 μM), before IBOP was added to the
chamber. After 16 hr of treatment, cells that invaded to the bottom of transwell chamber were
fixed and photographed. IBOP treatment stimulated the invasive capability of PC3-TPα cells in
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the in vitro invasion assay, whereas the vehicle, antagonist, Gefitinib, Compound-C reduced the
invasive capability of PC3-TPα cells (A, B). Similar results were obtained with DU145 cells that
have higher endogenous TPα expression (C). Representative phase contrast microscope
pictures are shown in correlation with the invasion assay from three independent experiments. It
was also quantified by counting the number of cells that invaded to the lower side of the filter in
three representative fields in each independent experiment.

TPα signaling results in larger tumors in a mouse model:
To examine the physiological relevance of increased colony formation and
invasion brought on by TP-α expression and signaling in PCa cells, we introduced PC3TPα or PC3-Neo cells into athymic mice in an established subcutaneous (s.c.) xenograft
tumor model to assess tumor growth in vivo. Prostate cancer cell proliferation in vitro
was largely comparable between PC3-TPα and PC3-Neo cells. This suggested that
PC3-TPα transfectants did not have a growth advantage over PC3-Neo cells in vitro
(Data not shown).
However mice that received PC3-TPα cells formed larger tumors compared to
mice injected with PC3-Neo cells, indicating that TPα transfected PC3 cells had an in
vivo growth advantage compared to Neo controls. (Figures 3.17, 3.18 A, B). Weekly
measurements over a 7-8 week period, revealed that tumors originating from PC3-TPα
cells injected into nude mice grew faster compared to PC3-Neo mice. (Figure 3.17)
After 7-8 weeks, mice were sacrificed as per the animal protocol, and tumors resected
from the mice receiving PC3-TPα were larger and found to weigh approximately twice
that of tumors originating from PC3-Neo-injected mice. (Figure 3.18 A, B, C, D)
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Figure 3.17: Mice bearing PC3-TPα cells showed greater tumor growth compared to the
control group. Increases in tumor growth in mice injected with PC3-TPα transfectants were
observed compared to PC3-Neo controls. Tumor growth was plotted for 7-8 weeks and a growth
curve was obtained.

3.18: Size and weight Comparison of tumors originating from PC3 vector controls
and PC3 cells overexpressing TPα
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Figure 3.18: Size and weight Comparison of tumors originating from PC3 vector controls
and PC3 cells overexpressing TPα. PC3 cells over expressing TPα yielded larger tumors
in vivo compared to PC3 parental cells carrying the expression vector alone. Mice (n=6)
receiving PC3-TPα (A) and mice (n=6) receiving PC3-Neo (B) were photographed on Day-56
after they were sacrificed. Tumors excised from mice injected with PC3-TPα cells were larger in
size compared to the PC3-Neo controls (C). Tumors excised from mice injected with PC3-TPα
cells displayed twice the weight (D) compared to the PC3-Neo controls. Weight of the mice
displayed on the graph is average weight of each group of mice (n=6) (D).

Angiogenesis plays an important role in tumor growth and is considered a key
step in tumor development. We found significant vascularization in tumors derived from
TPα transfected PC3 cells, whereas the PC3-Neo control tumors showed little vessel
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penetration. (Figure 3.19A) Paraffin-embedded tumor sections from mouse xenografts
of PC3-TPα cells or PC3-Neo cells were immunostained using antibodies specific for
CD31, which is an endothelial cell marker (Fig 3.19C). Real-time PCR on the cDNA
from tumors also confirmed the increased expression of CD31 in PC3-TPα tumors
compared to controls (Fig 3.19B).
To confirm whether increase in proliferation due to EGFR signaling was
responsible for increased tumor size seen in PC3-TPα mice, Paraffin-embedded tumor
sections from mouse xenografts of PC3-TPα cells or PC3-Neo cells were
immunostained using antibodies specific for KI67, which is an proliferation marker (Fig
3.19C). Immunohistochemistry analysis of the tumors sections also confirmed the
stronger staining for Ki67 in PC3-TPα tumors compared to controls (Fig 3.19D).
Our in vitro data revealed that IBOP activation of TPα enhanced cellular AREG
and EGFR levels. Therefore, mouse tumors were examined for expression of these
downstream targets. Analysis of cDNA generated from the tumor samples revealed that
EGFR, as well as AREG, VEGF and IL6 were in fact over expressed in tumors
originating from PC3-TPα transfectants (Figure. 3.20B). Furthermore, it was confirmed
that PC3-TPα cells maintained elevated expression levels of TPα compared to PC3Neo controls over the duration of the six week in vivo growth experiment. (Figure.
3.20A)

91

92

Figure 3.19: Increased neo vascularization and proliferation was observed in tumors from
mice harboring PC3-TPα cells compared to those given vector controls. Comparison of
vessel density of tumors ex vivo from PC3-TPα mice compared to control mice (A). Presence of
CD31, a prominent angiogenesis marker, was increased at the mRNA levels in mice injected
with PC3-TPα compared to PC3-Neo controls (B). Immunohistochemical analysis for CD31, an
endothelial marker, showed that sections from PC3-TPα tumors were strongly positive for CD31
(C). Arrowheads show the staining regions for CD31. Immunohistochemical analysis for Ki67, a
proliferation marker, showed that sections from PC3-TPα tumors were strongly positive for Ki67
(D). Arrowheads show the staining regions for Ki67.
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Figure 3.20: Increased expression of downstream target genes known to affect tumor
growth. In order to determine whether increased tumor growth in PC3-TPα, injected mice is due
to increased expression of either pro angiogenic factors or growth factors, RNA isolated from
mouse tumors was converted to cDNA and gene expression was quantified using Real-time
PCR. PC3-TPα transfectants maintained high TPα receptor levels in mouse tumors for the
duration of the study (A). Elevated TPα levels were associated with increased expression of
target genes such as AREG, EGFR, VEGF-A and IL6 (B). Values expressed represent the
mean fold change ± SEM, compared to vector control mice and is derived from three
experiments normalized in each case to GAPDH gene expression. Similar results were
observed in a further two independent experiments.
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Activation of TPα also promotes increased angiogenesis in a mouse model:
Increased neo vascularization was seen in PC3-TPα tumors as well as increased
expression of VEGF-A mRNA. This implied TPα might also lead to tumor growth by
playing a role in angiogenesis.
The increased angiogenicity due to TPα mediated VEGF expression in PC3-TPα
tumors was confirmed by the Matrigel implantation assay in an in vivo xenograft mouse
model. As shown in Fig. 3.21, within 12 days, TPα transfected PC3 cells (PC3-TPα) in
matrigel induced increased angiogenesis, indicated by the accumulation of blood in the
gel, compared to the neo control (PC3-Neo). The results clearly illustrate that the TPα
transfected PC3 cells are more angiogenic than their neo controls.
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Figure 3.21: Induction of angiogenesis in Matrigel by TPα transfectants: PC3-TPα cells or
PC3-Neo control cells (2xI06) were mixed with matrigel BME and injected s.c. into the right flank
of 4-6-week-old male SCID mice (n=6). In Mice injected with PC3-TPα cells mixed with Cultrex
BME, there was increased vessel penetration into the gel and considerable blood accumulation
was observed (A). In contrast, mice injected with PC3-Neo cells mixed with Matrigel BME, the
vessel penetration into the gel was minimal, with little blood accumulation (B).
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Chapter-4: Summary and Discussion:

Development of prostate cancer (PCa) is a multistep process. A key step in this
process is the overexpression of growth factors and their receptors that results in the
progression of normal prostate epithelial cells to a hyper proliferative cancer cell [171,
172]. Changes in gene expression of growth factors and their corresponding receptors
in epithelial and stromal cells during the different developmental stages of prostate
cancer contribute to enhanced tumor cell growth, survival, migration and invasiveness
[171, 172]. Among these, the ErbB family of receptors and their ligands, the EGF family
of peptide growth factors, has a central role in the pathogenesis and progression of
different carcinoma types [141, 144, 146, 150]. In particular, epidermal growth factor
receptor (EGFR) signaling has been associated with a wide variety of tumors and
causes PCa to progress by becoming invasive and metastatic [170, 171] [173, 174].
In this study, we report for the first time that activation of TPα signaling can lead to
over expression of AREG, a ligand of EGFR in prostate cancer cells. Our data also
indicate that activation of TPα not only upregulates AREG expression, but also
increases the expression of its cognate receptor EGFR. We also have demonstrated
that of the two TP receptor isoforms, only TPα receptor is expressed in PCa cells and
tissues. These findings suggest an alternate mechanism by which TPα can activate
EGFR signaling pathways leading to increased tumor growth. The experimental
evidence from this study has revealed molecular mechanisms underlying the enhanced
expression of AREG in prostate cancer. Our data indicate that the AMPK pathway plays
an important role in the expression of AREG mediated by TPα in PCa cells.
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Recent studies have shown that GPCRs are able to utilize the EGFR as a
downstream signaling partner in the generation of growth signals that might play an
important role in various cancers [124, 125, 128]. Studies have identified that EGFR as
an essential link in the GPCR-mediated activation of downstream signaling pathways
such as MAPK pathways in several cell types treated with the GPCR agonists [128,
197-199]. The TP receptor also uses EGFR as an essential link in the activation of
downstream signaling pathways. Two mechanisms i.e. ligand-dependent (shedding of
HB-EGF by MMPs) or ligand-independent (Src kinase mediated) have been proposed
that involve transactivation of EGFR by phosphorylation that leads to activation of
downstream signaling pathways [127] [126]. These models were established in HEK
cells over-expressing TP receptor-EGFR crosstalk has been established using HEK
cells overexpressing TP receptor and they have not examined in cancer cells. Therefore
alternate pathways involved in activation of EGFR by TP receptor are possible.
In this study we have proposed a novel mechanism by which EGFR can be
activated in PCa cells through GPCR. Our data show for the first time that increased
expression of AREG in response to TP stimulation by its agonist can lead to EGFR
activation in PCa cells. Our data also confirm that increased levels of AREG, seen in
response to stimulation of TPα, result in functional binding to EGFR, leading to EGFR
phosphorylation and activation of downstream MAPK pathways. Elevated AREG could
then lead to constitutive EGFR signaling and activation of downstream signaling
pathways involved in cellular proliferation, cell migration, cell survival, and
angiogenesis. Overexpression of AREG has been reported in both androgen dependent
and independent prostate cell lines as well as tissues. However the specific pathways
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leading to AREG expression have not yet been elucidated [157, 158, 175]. Our study
sheds light on a novel pathway, where we found that activation of TPα led to increased
expression of AREG. This presents a mechanistic explanation for those findings, as we
also determined that TPα is over-expressed in PCa cell lines.
We discovered that TPα activation also led to over expression of EGFR. It is
known that AREG acts exclusively through EGFR, where it binds EGFR with a lower
affinity than EGF, and induces receptor autophosphorylation and downstream activation
of the ERK signaling cascade [156, 158]. One of the most studied receptor tyrosine
kinases i.e. EGFR and its signaling pathway is central to both physiological and
pathophysiological process [139, 140, 143, 144, 150]. Over-expression of EGFR or upregulation of its signaling pathway has been associated with several cancers and has
led to uncontrolled cellular proliferation and autocrine stimulation of tumors producing
their own growth factors [141, 146, 149, 150, 200]. The enhanced expression of EGFR
and its ligands, EGF, TGF-α, HB-EGF and AREG, has been reported to correlate with
high grades of PCa malignancies [158, 174].
The mechanisms responsible for AREG upregulation in transformed cells
are not fully understood and might vary from one tumor subtype to another. Recent
studies have shown that AREG can be induced by cAMP pathway in various cell types
[160]. A cAMP-responsive element (CRE) has been described in the AREG promoter
and expression of AREG is regulated by cAMP [160, 161]. AREG can also be regulated
by EGFR itself, and activation of EGFR leads to AREG expression in several cell types
[155, 157, 166, 168]. We investigated and determined that activation of TPα clearly
increases the cAMP levels in PCa cell lines. These findings and other studies point to a
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possible role for cAMP and EGFR in over expression of AREG that is induced by TPα
signaling.
As our data indicate, blocking EGFR activation with EGFR inhibitors (Gefitinib,
AG1478) actually reduced AREG levels in TPα over-expressing cells, that TPα
upregulates AREG mRNA by direct activation of EGFR via EGFR phosphorylation.
Inhibition of PKA (downstream mediator of cAMP) prior to EGFR inhibition did not affect
the expression of AREG. The possibility of an alternate pathway involving cAMP [160]
led us to consider whether the AMPK pathway was involved. The thromboxane receptor
reportedly can activate the AMP-activated protein kinase in vascular smooth muscle
cells via hydrogen peroxide [190]. Treatment with the AMPK inhibitor (Compound-C) led
to a decrease in AREG both at the level of mRNA and protein (Figure 3.15). Therefore
we have identified the AMPK pathway as the key signaling pathway triggered by TPα to
increase AREG expression in human prostate cancer cells.
Aberrant EGFR and AREG signaling has been recognized to affect cellular
proliferation, cell migration, cell survival, and angiogenesis [141, 144, 146, 150]. Many
of these key steps in cancer progression are also regulated by TP receptor. Previous
studies from our lab have shown that activation of TPα receptor by IBOP induces cell
motility through the Rho-A pathway [101]. As AREG had been shown to upregulate
several genes known to be involved in motility and invasion in breast cancer cells [155,
156, 168], we investigated whether TPα-AREG-EGFR signaling plays a role in PCa cell
invasion. Our invasion assays showed that TPα does in fact play a role in cell invasion,
and is mediated by EGFR signaling. Our data also confirm that increased expression of
AREG induced by TPα receptor promoted cell invasion, as blocking AREG expression
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with AMPK inhibitors reduced invasion. These data indicate that PCa cells expressing
AREG in response to TPα receptor stimulation require autocrine signaling through
EGFR for cell invasion to occur.
Activation of TPα receptor in PC3-TPα cells by IBOP promoted increased
expression of growth factors such as AREG and its receptor EGFR thereby playing a
role in tumor growth. Using a xenograft mouse model, we demonstrated that TPα
transfected PC3 cells formed larger tumors than vector controls, and that the increased
tumor volume was positively correlated with enhanced tumor angiogenesis. Tai et al.,
have shown that overexpression of TPα in A549 lung cancer cells also led to enhanced
tumor angiogenesis and growth in a xenograft animal model [201]. Taken together,
these studies suggest that expression of TPα in cancer cells can enhance their
angiogenic potential through expression of growth factors leading to tumor growth. We
found significant vascularization in tumors derived from PC3-TPα cells, compared to
PC3-Neo tumors. Formalin fixed paraffin-embedded tumor sections from these mice
showed very strong CD31 staining. Analysis of tumors from PC3-TPα mice by real-time
PCR showed increased expression of pro-angiogenic growth factors and cytokines such
VEGF and IL6.
Angiogenesis is a multistep process that requires the concerted action of
numerous growth factors. VEGF is an important angiogenic factor that had been
correlated with poor prognosis and improved survival of solid tumors. Expression and
secretion of VEGF is triggered by a vast multitude of factors and signaling pathways in
cancer cells [202, 203]. In solid tumors, the VEGF and EGFR pathways are linked with
respect to angiogenesis [204, 205]. EGFR ligands such as EGF and TGF-α can induce
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VEGF expression via activation of EGFR in cell culture models and have proangiogenic
properties [204, 205]. It is likely that the EGFR pathway modulates angiogenesis by upregulating VEGF or other key mediators in the angiogenic process [206]. The increased
angiogenicity due to TPα mediated VEGF expression in PC3-TPα tumors was
confirmed by the Matrigel implantation assay in an in vivo xenograft mice model
indicating that increased EGFR signaling mediated by TPα to be responsible for it.
In this study, we identified which TP receptor isoform is predominantly expressed
in PCa cells and tissues. Though the existence of two TP isoforms was described as
early as 1994, most of the earlier studies on TP did not distinguish the functional roles
between the two isoforms and it was assumed that most of the functional effects of TP
to be mediated by TPα. Recent findings though provide a novel role for TPβ in bladder
cancer progression [99]. Until now the expression status of TP isoforms was largely
uncharacterized in prostate cancer cells and tissues. Identification of the active isoform
in prostate cancer will help us to design isoform-specific antagonists or inhibitors that
uniquely target this pathway for greater therapeutic impact.
One of the technical challenges in working with TP isoforms is the lack of
isoform-specific antibodies. The only difference between TPα and TPβ is that TPα has a
shorter C-terminal cytoplasmic tail than the TPβ isoform (15 versus 79 residues) [5254]. Currently there are no commercially available antibodies that can discriminate
these two isoforms. To distinguish them, we designed Taqman gene expression assays
specific for each TP isoform and were able to differentiate their expression level in PCa
cells and tissues. Within the detection boundaries of this assay, TPα appeared to be
solely expressed isoform in PCa cell lines and tissues. We used several approaches
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(Immunoblot, RT-PCR, Real-time PCR, cAMP enzyme Immunoassay) to look into the
possible expression of both TP isoforms in PCa, but our data strongly pointed that only
TPα expression is seen in PCa cells. Data from our tissue array analysis show that TPα
expression is higher in prostate cancer tissues compared to normal prostate tissues.
Collectively, the data-mining results and the data from Real-time PCR analysis of
human tissue arrays make a strong case for the association of TPα expression with the
aggressiveness and progression of prostate tumors. Previous studies by Bostwick et al.
were able to conclude that increased expression of AREG might contribute to the
development of prostatic adenocarcinoma [158].
EGFR protein was found by Marks et al. to be frequently expressed in tissue
from prostate cancer patients undergoing hormone therapy [207]. In 57 of 71 patients
undergoing hormonal therapy, there was demonstrable EGFR expression by
immunostaining. More studies will be needed to focus on the co-expression levels of
both TPα and AREG in prostate cancer tissues in relation to EGFR so as to determine
their connectivity. In gastric cancer cell lines, Cetuximab responsiveness against EGFR
was associated with AREG levels, and Cetuximab treatment attenuated AREG, while
EGF elevated AREG. This implies that the EGFR pathway itself appears to regulate
AREG[208]. It is known that TPR activation includes the expression of a nuclear
receptor called Nurr1 that can stimulate proliferation of lung cancer cells [119]. In turn,
Nurr1 has been shown to regulate pro-inflammatory mediators, including AREG, in
synovial fibroblasts [209]. As both TPα and AREG are over expressed in PCa tissues, it
will be interesting if links such as those implied by the Nurr1 studies play a role in TPαmediated expression of in human PCa tissues.
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Conclusion:
In summary, our study has identified a novel link between TPα signaling and
AREG expression in prostate cancer cells. We report for the first time that activation of
TPα signaling in PCa cells can lead to increased expression of AREG and its receptor
EGFR, and that AMPK plays an important role in regulation of AREG by TPα. EGFR
signaling has been recognized to be at the forefront of aberrant signal transduction
pathways, involved in cellular proliferation, cell migration, cell survival, and
angiogenesis. Over expression of TPα in PC3 cells can result in increased invasiveness
of PCa cells, which might be mediated by EGFR signaling pathways.
Over expression of TPα in PC3 cells led to increased tumor growth and
angiogenesis in a xenograft mouse model that is likely associated with increased
expression of AREG, VEGF and EGFR signaling. We report for the first time that TPα
mRNA expression is elevated in the prostate cancer tissues and conclude that TPα
expression in PCa tissues correlates with aggressiveness of the disease.

These

findings suggest that the functional role of TPα in prostate cancer progression might
involve increased expression of AREG leading to increased activation of EGFR
signaling promoting angiogenesis, cell invasion and tumor growth.
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Project Summary

	
  
Figure 4: Summary of TPα receptor mediated AREG expression and EGFR signaling in
prostate cancer cells

Future Directions:
Recent emphasis in prostate cancer research has been on identification of
candidate genes that are good prognostic or predictive markers. As defined by Busser
et al., “Prognostic factors provide information on the outcome of the disease, whereas
predictive factors are used to prospectively select responsiveness or resistance to a
specific treatment” [169]. TPα appears to be an ideal candidate to be considered as a
prognostic marker in prostate cancer. TPα was more highly expressed in aggressive
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forms of PCa and correlated with Gleason scores. A significant finding from our studies
was that TPα expression was elevated in GS7 (4+3) compared to GS7 (3+4), which
suggests that differences in TPα expression exist between primary and secondary
patterns. Further studies are needed in statistically relevant sample set to see whether
this can potentially be exploited as a biomarker for discriminating GS7 subtypes when
making prognostic determinations.
Further in vivo studies will clarify the actual role of EGFR and AREG in TPαmediated tumor growth. This could be approached by knocking down either AREG or
EGFR in PC3 cells over expressing TPα, injecting them into mice, and following tumor
growth. Further elucidation of TPα-mediated pathways that elevate expression of AREG
and lead to subsequent tumor cell growth will provide insights into the key steps
involved in prostate cancer progression. Inhibition of growth factors and their receptor
signaling pathways has proven to be an effective approach to block tumor growth.
Therefore, inhibition of TPα signaling by antagonists, or prevention of TXA2 synthesis by
inhibiting TXA2S, may be a novel approach to develop anticancer, anti-angiogenic
therapy [210]. It remains to be determined if TPα and AREG expression in prostate
cancer tissue can be correlated to each other.
The low cost of aspirin has kept it in the forefront of treatment in cardio
vascular disorders, whereas TXA2S inhibitors and TXA2 antagonists have not been
employed for clinical benefits. Conversely, current therapeutic regimens for cancer
incorporate few agents of the NSAID class, which makes TXA2S/TP antagonism an
attractive target with potentially significant therapeutic benefit. Moreover, in contrast to
NSAIDs, TXA2S/TP inhibitors do not interfere with synthesis of other beneficial COX-
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derived anti-tumor products, such as PGI2 [211-216]. Hence, future work should focus
on the advantages of directly targeting TXA2S and/or developing TP antagonists or
taking advantage of the anti tumor effects of PGI2.
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Thromboxane A2 (TXA2) is a major arachidonic acid metabolite that signals
through TXA2 receptors (TP) to induce platelet aggregation and smooth muscle
contraction. TXA2 receptors are expressed as two different isoforms in humans, namely
TP-alpha (TPα) and TP-beta (TPβ), which have common and distinct signaling
pathways. Of the two TP receptor isoforms, studies have shown that TPα impacts tumor
growth and progression of lung cancer. Previously our studies demonstrated that
activation of Thromboxane receptor by TXA2 agonists could regulate prostate cancer
(PCa) cell motility and cytoskeletal reorganization through activation of Rho-A. The
primary objective of this study is to investigate the functional role of TPα in prostate
cancer progression and metastasis.
Our data indicates that of the two TPR isoforms, human PCa cell lines only
express TPα and that expression of TPα is higher in PCa cells compared to cultured
normal prostate epithelial cells, such as RWPE1. Furthermore, expression of TPα was
observed to be higher in clinical PCa specimens when compared with normal tissue,
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and expression was higher in tumor tissues with Gleason scores of 7 and above. In
response to the TXA2 mimetic, IBOP, DU145 cells that have higher endogenous levels
of TPα compared to other cell lines, up regulated expression of the growth factor
Amphiregulin (AREG) and its receptor EGFR. Introduction of an expression plasmid
encoding TPα into another PCa cell line, PC3 (PC3-TPα), led to a similar phenotype in
response to IBOP, thereby confirming a link between TPα and over expression of AREG
and EGFR.
Increase in AREG expression mediated by TPα seems to involve EGFR and
AMP activated protein kinase (AMPK) signaling pathways. PC3-TPα cells treated with
IBOP were also highly invasive compared to PC3-Neo cells; this invasiveness mediated
by TPα was affected by pre treatment with an EGFR inhibitor. In a subcutaneous animal
model, mice injected with PC3-TPα exhibited greater tumor growth and increased neo
vascularization compared to mice with PC3-Neo cells. Also when mice was injected with
PC3-TPα cells and Matrigel BME, increased angiogenesis was observed as indicated
by the accumulation of blood compared to mice with PC3-Neo cells. Collectively these
data suggest that activation of TPα receptor in PCa cells increases the level of growth
factors such as AREG and its receptor EGFR that might be mediated through AMPK,
thereby implicating TPα in prostate cancer progression.
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